

# NCASP IT Infrastructure project

## CSV Upload/Download File Specification

Version No: 2.1.2  
Issue Date: Nov 2007

**VERSION HISTORY**

Version	Date Issued	Brief Summary of Change	Owner's Name
Draft	13/11/2002	First Draft Version	Alan Scott
Draft 0.2	27/02/2003	Updated following review	Alan Scott
Draft 0.3	02/05/2003	Updated validation rules	Alan Scott
Draft 0.4	03/07/2003	Update file layout	Alan Scott
Draft 0.5	10/07/2003	Updated following Extended UAT	Andrew Stockley
Draft 0.6	04/11/2003	Addition of new data items	Richard Newberry
1.0	12/11/2003	Validation rules review	Richard Newberry
1.1	13/01/2004	Add Occult Carcinoma to TNM Category	Richard Newberry
1.2	23/02/2004	Differentiate between two data fields for Prophylactic Cranial Irradiation	Tim Rickwood
1.3	08/04/2004	Amendment to FEV1 % range, which is now 1 to 150.	Richard Newberry
1.4	17/06/2004	Amendment to include two new extra fields for site codes	Tim Rickwood
1.5	21/02/2005	Amendment to include OTHER as valid code for HISTOLOGY	Tim Rickwood
1.6	25/09/2006	Add Biphasic Mesothelioma	Tim Rickwood
2.0	04/12/2006	Phase 2 Release 1 changes	Tim Rickwood
2.1	17/05/2007	Phase 2 Release 1 Nurse Led Audit	Tim Rickwood
2.1.1	22/05/2007	Phase 2 Release 1 Extra validation	Tim Rickwood
2.1.2	05/11/2007	Phase 2 Release 1 Relaxed validation around key investigation dates	Tim Rickwood

**APPROVALS**

This document requires the following approvals:

Name	Signature	Title / Responsibility	Date	Version
R Stanley		National Lung Cancer Audit Project Manager (NCASP)	17/05/2007	2.1

<p>For more information on the status of this document, please see the covering letter or contact:</p>	<p>NHS Connecting for Health                  Hexagon House                  Pynes Hill                  Exeter                  EX2 5SE</p> <p>Tel: 01392 206842                  Fax: 01392 206946                  E-mail: tim.rickwood@nhs.net</p> <p>Internet: www.connectingforhealth.nhs.uk</p>
--	--

Date of Issue	Nov2007
File reference	CSV_Upload-Download_Spec v2.1.02.doc
© Crown Copyright 2005	

## Contents

<b>1. INTRODUCTION .....</b>	<b>5</b>
<b>2. FILE DESCRIPTION .....</b>	<b>5</b>
2.1. File Structure.....	5
2.2. File Validation .....	6
2.2.1. Demographic Validation (Upload) .....	6
2.2.2. Data Validation (Upload).....	6
2.2.3. Rejected records.....	12
2.2.4. Redundant data items .....	12
2.2.5. Data Items (Upload).....	13
2.2.6. Data Items (Single Organisation Download).....	24
2.2.7. Data Items (Download All Organisations - Anonymous).....	36
2.2.8. Data Items (Download All Organisations – Identifiable).....	49
<b>3. EXAMPLE RECORD (UPLOAD) .....</b>	<b>62</b>
<b>4. APPENDIX A – UPLOAD SCREEN .....</b>	<b>62</b>
<b>5. APPENDIX B – EXAMPLE OF REJECTED RECORDS .....</b>	<b>62</b>
<b>6. APPENDIX C – CELL HEADINGS .....</b>	<b>63</b>

# 1. INTRODUCTION

This document defines the format of the CSV upload and download files to the LUCADA implementation of the Clinical Audit for the National Clinical Audit Support Programme (NCASP) System.

The files defined in this document are:

- for upload to the LUCADA system. The LUCADA database will be updated with the values contained in the CSV upload file.
- for download of data of patient(s) from the LUCADA system.

The filenames for CSV files to be uploaded to LUCADA can be any valid name allowed by the Windows operating system. Good practice for naming files would include the date and the source of the data. The filename must have a file extension of '.csv' in order for the system to process it. Upper or lower case is acceptable.

The LUCADA system automatically generates the name of the file for download. The download filename will include the date and time of the download.

There is one format of CSV file for upload but currently three different possible formats for CSV download.

## 2. FILE DESCRIPTION

### 2.1. *File Structure*

Files are made up of variable length records, each record ending with a carriage return and line feed (ASCII 13,10). Each record will contain one patient's data. A file can contain one or multiple patient records.

The data in each record is split into fields by using a comma separator ( , ). The comma separator must also follow the last field in each record.

All fields can either contain one of the permitted values listed in the table below or be null/blank. Where codes are displayed in bold in the table below (with textual values in brackets), please use these codes in the upload file and NOT the text values as the record will be rejected.

#### **Permitted Values**

If the field contains a permitted value then all alphabetic characters MUST be UPPERCASE. If lowercase characters are used anywhere within the upload file then the whole file will be rejected on the basis of the incorrect format. All fields must contain double-quotes at the start and end to indicate that they are textual values (this also includes numerical values).

## Null/Blank Values

If the field is a null/blank value, i.e. no contents, then the field must still contain the double-quotes. E.g. for an empty field within the record the data would contain a comma, followed by two double-quotes and then a comma (,",").

## 2.2. File Validation

### 2.2.1. Demographic Validation (Upload)

The first nine fields are called 'Demographic' details. Within this section, the mandatory fields are:

- 'NHS NUMBER',;
- 'PATIENT FAMILY OR SURNAME',;
- 'BIRTH DATE' ; and
- 'ORGANISATION CODE (CODE OF PROVIDER)'.

The items

- 'PATIENT FORENAME OR PERSONAL NAME',;
- 'SEX'; and
- 'POSTCODE OF USUAL ADDRESS (AT DIAGNOSIS)'

are derived from the Patient Demographic Service (PDS). 'Age at time of diagnosis' is derived by the system on an Upload, from the 'BIRTH DATE' and 'DIAGNOSIS DATE (CANCER)' fields, hence it can remain blank within the double-quotes. 'CARE SPELL IDENTIFIER' should remain blank, as this field is not required in this release of the system.

The ORGANISATION CODE (CODE OF PROVIDER) is included in the download, but for an upload it is derived from the organisation code of the user who requested the upload, hence can remain blank within the double-quotes.

If any record's NHS Number, Patient Surname and Birth Date are different to those details held on the PDS, the record will not be entered into the database. Instead the user will receive an error message which indicates that the demographic details are in conflict and this will be displayed.

### 2.2.2. Data Validation (Upload)

There are certain data conditions that are not allowed. These restrictions are imposed in line with clinical expectations. (Numbers in brackets refer to field numbers in the table below.) It is important to realise how data validation is done. Any non-null values supplied for a subject in the upload file are inserted into a copy of that subject's record as held on the database. The revised copy of the record is then subjected to the following validation checks. It is possible therefore to upload a change to an existing record where the upload file has no data for date or place first seen (both mandatory items), because the existing record will have values for both those items. In addition to the specific rules itemised below there are some general rules:

- All dates must be in the format specified

- Future dates will be rejected
- No dates after date of death except date of diagnosis or date of investigation result.
- Only the itemised valid values for each data item will be accepted

1. **CANCER REFERRAL DECISION DATE (10)**
  - a. If not null, must be on or before the **DATE FIRST SEEN (11)**
2. **DATE FIRST SEEN (11)**
  - a. Must not be null
  - b. Must be on or after the **CANCER REFERRAL DECISION DATE (10)**
3. **SITE CODE OF PLACE FIRST SEEN (12)**
  - a. Must not be null
  - b. Must be valid OCS Hospital code
4. **DIAGNOSIS DATE (14)**
  - a. Must be after the **BIRTH DATE (3)**
  - b. Date must be after **DATE FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST (110)** if **AT WHAT STAGE(S) IN THE PATIENT PATHWAY DID ASSESSMENT BY LUNG CANCER NURSE SPECIALIST OCCUR (112)** is either:
    - i. BEFORE DIAGNOSIS; or
    - ii. BEFORE AND AFTER DIAGNOSIS
5. **SITE CODE (DIAGNOSIS) (15)**
  - a. Must be valid OCS Hospital code
6. **PRIMARY DIAGNOSIS (16)**
  - a. The following values :
    - i. MALIGNANT NEOPLASM OF BRONCHUS OR LUNG
    - ii. MAIN BRONCHUS, CARINA, HILUS OF LUNG
    - iii. (UPPER LOBE, BRONCHUS OR LUNG (INCLUDING PANCOAST)
    - iv. MIDDLE LOBE / LINGULAR, BRONCHUS OR LUNG
    - v. LOWER LOBE, BRONCHUS OR LUNG
    - vi. OVERLAPPING LESION OF BRONCHUS AND LUNG)
    - vii. BRONCHUS OR LUNG, UNSPECIFIED
    - viii. TRACHEA
    - ix. MALIGNANT NEOPLASM OF HEART, MEDIASTINUM AND PLEURA)
    - x. PLEURA
    - xi. MEDIASTINUM, PART UNSPECIFIED
    - xii. OVERLAPPING LESION OF HEART, MEDIASTINUM AND PLEURA

are only valid if **PRE TREATMENT (HISTOLOGY) (26)** is *not* :

    - i. MALIGNANT MESOTHELIOMA (NOS); or
    - ii. MESOTHELIOMA (EPITHELIOID) ; or
    - iii. MESOTHELIOMA (SARCOMATOID) ICD-O-3 ; or
    - iv. BIPHASIC MESOTHELIOMA
  - b. The following values:
    - i. Null; or
    - ii. MESOTHELIOMA; or
    - iii. MESOTHELIOMA OF PLEURA

are only valid if **PRE TREATMENT (HISTOLOGY) (26)** is either

    - i. Null (ie left blank)
    - ii. MALIGNANT MESOTHELIOMA (NOS); or

- iii. MESOTHELIOMA (EPITHELIOID) ; or
- iv. MESOTHELIOMA (SARCOMATOID) ICD-O-3 ; or
- v. BIPHASIC MESOTHELIOMA

**7. M CATEGORY (FINAL PRE-TREATMENT) (21)**

- a. M0 is not a valid option if BASIS OF DIAGNOSIS (18) is :
  - i. HISTOLOGY OF A METASTASIS

**8. HISTOLOGY (SNOMED) (PRE-TREATMENT) (26)**

- a. The following values :
  - i. MALIGNANT MESOTHELIOMA (NOS); or
  - ii. MESOTHELIOMA (EPITHELIOID) ; or
  - iii. MESOTHELIOMA (SARCOMATOID) ICD-O-3 ; or
  - iv. BIPHASIC MESOTHELIOMA

are only valid if PRIMARY DIAGNOSIS (16) is

- i. Null; or
- ii. MESOTHELIOMA; or
- iii. MESOTHELIOMA OF PLEURA

- b. The following values :

- i. CARCINOMA IN SITU
- ii. SECONDARY CARCINOMA
- iii. LARGE CELL CARCINOMA NOS
- iv. LARGE CELL – UNDIFFERENTIATED
- v. SMALL CELL CARCINOMA
- vi. NON-SMALL CELL CARCINOMA (ICD-O-3)
- vii. SQUAMOUS CELL CARCINOMA NOS
- viii. ADENOCARCINOMA NOS
- ix. CARCINOID NOS
- x. LARGE CELL NEUROENDOCRINE (ICD-O-3)
- xi. BRONCHIO-ALVEOLAR CELL CARCINOMA
- xii. MIXED TUMOUR
- xiii. CARCINOSARCOMA NOS
- xiv. OTHER

are invalid if PRIMARY DIAGNOSIS (16) is

- i. MESOTHELIOMA; or
- ii. MESOTHELIOMA OF PLEURA

- c. Must be null if the BASIS OF DIAGNOSIS (18) is :

- i. SPECIFIC TUMOUR MARKERS;
- ii. CLINICAL INVESTIGATION; or
- iii. CLINICAL

**9. SITE-SPECIFIC STAGING CLASSIFICATION (27)**

- a. Valid value only required if HISTOLOGY (SNOMED) (PRE-TREATMENT) (26) is SMALL CELL TUMOUR.

- b. Must be null if the BASIS OF DIAGNOSIS (18) is :

- i. SPECIFIC TUMOUR MARKERS;
- ii. CLINICAL INVESTIGATION; or
- iii. CLINICAL

**10. MULTIDISCIPLINARY TEAM DISCUSSION DATE (29)**

- a. Only required if MDT DISCUSSION INDICATOR (28) is TRUE

**11. DEMENTIA/CEREBROVASCULAR DISEASE (35)**

- a. Only required if REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT (89) is either

- i. CO-MORBIDITY PRECLUDING TREATMENT
  - ii. COPD
- 12. **CARDIOVASCULAR DISEASE (36)**
  - a. Only required if REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT (89) is either
    - i. CO-MORBIDITY PRECLUDING TREATMENT
    - ii. COPD
- 13. **RENAL FAILURE (37)**
  - a. Only required if REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT (89) is either
    - i. CO-MORBIDITY PRECLUDING TREATMENT
    - ii. COPD
- 14. **OTHER MALIGNANCY (38)**
  - a. Only required if REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT (89) is either
    - i. CO-MORBIDITY PRECLUDING TREATMENT
    - ii. COPD
- 15. **SEVERE WEIGHT LOSS (39)**
  - a. Only required if REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT (89) is either
    - i. CO-MORBIDITY PRECLUDING TREATMENT
    - ii. COPD
- 16. **OTHER SIGNIFICANT WEIGHT LOSS (40)**
  - a. Only required if REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT (89) is either
    - i. CO-MORBIDITY PRECLUDING TREATMENT
    - ii. COPD
- 17. **FEV1 ABSOLUTE AMOUNT (41)**
  - a. Must be a numeric in the range of 0.10 to 10.00.
- 18. **FEV1 PERCENTAGE (42)**
  - a. Must be an integer in the range of 1 to 150.
- 19. **SITE CODE (OF SURGERY) (44)**
  - a. Must be valid OCS Hospital code
- 20. **PROCEDURE DATE (SURGERY) (46)**
  - a. Must not be before LUNG CANCER SPECIALIST REFERRAL DATE (13)
  - b. Must not be before DATE FIRST SEEN (11)
  - c. Must not be after Investigation Result Date (75)
- 21. **EXCISION MARGIN (49)**
  - a. Only required if there is data recorded for PRIMARY PROCEDURE (47)
- 22. **SITE CODE (OF ANTI-CANCER DRUG TREATMENT) (57)**
  - a. Must be valid OCS Hospital code
- 23. **DECISION TO TREAT DATE (ANTI-CANCER DRUG REGIMEN) (58)**
  - a. Must not be before CANCER REFERRAL DECISION DATE (10)
  - b. Must not be before LUNG CANCER SPECIALIST REFERRAL DATE (13)
  - c. Must not be before DATE FIRST SEEN (11)
- 24. **START DATE (ANTI-CANCER DRUG REGIMEN) (59)**
  - a. Must not be before CANCER REFERRAL DECISION DATE (10)
  - b. Must not be before LUNG CANCER SPECIALIST REFERRAL DATE (13)
  - c. Must not be before DATE FIRST SEEN (11)
  - d. Must not be before DECISION TO TREAT DATE (ANTI-CANCER DRUG REGIMEN) (58)

25. [SITE CODE \(OF TELETHERAPY\) \(62\)](#)
  - a. Must be valid OCS Hospital code
26. [START DATE \(TELETHERAPY TREATMENT COURSE\) \(66\)](#)
  - a. Must not be before [CANCER REFERRAL DECISION DATE \(10\)](#)
27. [SITE CODE \(OF BRACHYTHERAPY\) \(67\)](#)
  - a. Must be valid OCS Hospital code
28. [START DATE \(BRACHYTHERAPY TREATMENT COURSE\) \(69\)](#)
  - a. Must not be before [DECISION TO TREAT DATE \(BRACHYTHERAPY TREATMENT COURSE\) \(68\)](#)
29. [SITE CODE \(SPECIALIST PALLIATIVE TREATMENT COURSE\) \(70\)](#)
  - a. Must be valid OCS Hospital code
30. [START DATE \(SPECIALIST PALLIATIVE TREATMENT COURSE\) \(72\)](#)
  - a. Mandatory if [PALLIATIVE CARE.INTERVENTIONAL TREATMENT GIVEN \(102\)](#) is TRUE.
31. [SITE CODE \(ACTIVE MONITORING\) \(73\)](#)
  - a. Must be valid OCS Hospital code
32. [INVESTIGATION RESULT DATE \(75\)](#)
  - a. Must not be before [SURGICAL PROCEDURE DATE \(46\)](#)
33. [POST TREATMENT: SITE SPECIFIC CLASSIFICATION \(77\)](#)
  - a. Only required if [HISTOLOGY - POST TREATMENT \(76\)](#) is SMALL CELL TUMOUR.
34. [WAS DEATH RELATED TO TREATMENT \(80\)](#)
  - a. Only required if there is date recorded for [DEATH DATE \(79\)](#)
35. [ORIGINAL TREATMENT PLAN CARRIED OUT \(87\)](#)
  - a. TRUE is only valid if the [SUGGESTED CANCER TREATMENT PLAN \(86\)](#) is not null.
  - b. FALSE is only valid if the [SUGGESTED CANCER TREATMENT PLAN \(86\)](#) is not null.
  - c. If the [SUGGESTED CANCER TREATMENT PLAN \(86\)](#) included Surgery, then TRUE is only valid if [DECISION TO TREAT DATE \(SURGERY\) \(45\)](#) is not null.
  - d. If the [SUGGESTED CANCER TREATMENT PLAN \(86\)](#) included Active Monitoring then TRUE is only valid if [DECISION TO TREAT DATE \(ACTIVE MONITORING\) \(74\)](#) is not null.
  - e. If the [SUGGESTED CANCER TREATMENT PLAN \(86\)](#) included Specialist Palliative Care then TRUE is only valid if [DECISION TO TREAT DATE \(SPECIALIST PALLIATIVE TREATMENT COURSE\) \(71\)](#) is not null.
  - f. If the [SUGGESTED CANCER TREATMENT PLAN \(86\)](#) included Brachytherapy then TRUE is only valid if [DECISION TO TREAT DATE \(BRACHYTHERAPY TREATMENT COURSE\) \(68\)](#) is not null.
  - g. If the [SUGGESTED CANCER TREATMENT PLAN \(86\)](#) included Chemotherapy then TRUE is only valid if [DECISION TO TREAT DATE \(ANTI-CANCER DRUG REGIMEN\) \(58\)](#) is not null
  - h. If the [SUGGESTED CANCER TREATMENT PLAN \(86\)](#) included Teletherapy then TRUE is only valid if [DECISION TO TREAT DATE \(TELETHERAPY TREATMENT COURSE\) \(63\)](#) is not null.
36. [ORIGINAL TREATMENT PLAN CARRIED OUT \(87\)](#)
  - a. TRUE is only valid if [ORIGINAL TREATMENT PLAN FAILURE REASON \(88\)](#) is null
37. [ORIGINAL TREATMENT PLAN FAILURE REASON \(88\)](#)
  - a. Must be null if [ORIGINAL TREATMENT PLAN CARRIED OUT \(87\)](#) is TRUE.
38. [DATE OF CT SCAN \(91\)](#)
  - a. Only required if [CT SCAN \(90\)](#) is TRUE

39. **DATE OF PET OR PET/CT SCAN (93)**
- Only required if **PET OR PET/CT SCAN (92)** is TRUE
  - Must not be before **DATE FIRST SEEN (11)**
40. **DATE OF BRONCHOSCOPY (95)**
- Only required if **BRONCHOSCOPY (94)** is TRUE
  - Must not be before **DATE FIRST SEEN (11)**
41. **DATE OF DIAGNOSTIC BIOPSY (97)**
- Only required if **DIAGNOSTIC BIOPSY (96)** is TRUE
42. **DATE OF CT GUIDED BIOPSY (99)**
- Only required if **CT GUIDED BIOPSY (98)** is TRUE
43. **DATE INTERVENTIONAL TREATMENT GIVEN (103)**
- Mandatory if **PALLIATIVE CARE.INTERVENTIONAL TREATMENT GIVEN (102)** is TRUE
44. **PALLIATIVE CARE.COMMUNITY PROVIDER TYPE (101)**
- Only required if **PALLIATIVE CARE.PROVIDER TYPE (100)** is COMMUNITY
45. **SITE CODE (SPECIALIST PALLIATIVE TREATMENT COURSE) (70)**
- Only required if **PALLIATIVE CARE.PROVIDER TYPE (100)** is HOSPITAL
46. **STAGING PROCEDURE UNKNOWN (108)**
- Only needed if **STAGING PROCEDURE PERFORMED (104)** is TRUE
  - Not needed if any of the following staging procedures are TRUE.
    - STAGING PROCEDURE OTHER STAGING (107)**
    - STAGING PROCEDURE PERFORMED FNA (106)**
    - STAGING PROCEDURE MEDIASTINOSCOPY MEDIASTINOTOMY (105)**
47. **STAGING PROCEDURE OTHER STAGING (107)**
- Only needed if **STAGING PROCEDURE PERFORMED (104)** is TRUE
48. **STAGING PROCEDURE PERFORMED FNA (106)**
- Only needed if **STAGING PROCEDURE PERFORMED (104)** is TRUE
49. **STAGING PROCEDURE MEDIASTINOSCOPY MEDIASTINOTOMY (105)**
- Only needed if **STAGING PROCEDURE PERFORMED (104)** is TRUE
50. **DATE FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST (110)**
- Date only required if **PATIENT ASSESSED BY A LUNG CANCER NURSE SPECIALIST (109)** is TRUE
  - Date must be before **DIAGNOSIS DATE (14)** if **AT WHAT STAGE(S) IN THE PATIENT PATHWAY DID ASSESSMENT BY LUNG CANCER NURSE SPECIALIST OCCUR (112)** is either:
    - BEFORE DIAGNOSIS; or
    - BEFORE AND AFTER DIAGNOSIS
  - Date must not be before **LUNG CANCER SPECIALIST REFERRAL DATE (13)**
51. **HOW WAS PATIENT FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST (111)**
- Data only required if **PATIENT ASSESSED BY A LUNG CANCER NURSE SPECIALIST (109)** is TRUE
52. **AT WHAT STAGE(S) IN THE PATIENT PATHWAY DID ASSESSMENT BY LUNG CANCER NURSE SPECIALIST OCCUR (112)**
- Data only required if **PATIENT ASSESSED BY A LUNG CANCER NURSE SPECIALIST (109)** is TRUE
53. **LUNG CANCER NURSE SPECIALIST PRESENT WHEN PATIENT RECEIVED DIAGNOSIS (113)**

- a. If [AT WHAT STAGE\(S\) IN THE PATIENT PATHWAY DID ASSESSMENT BY LUNG CANCER NURSE SPECIALIST OCCUR \(112\)](#) is “WHEN PATIENT RECEIVED DIAGNOSIS ONLY”, then only valid value is TRUE.
- b. Data only required if [PATIENT ASSESSED BY A LUNG CANCER NURSE SPECIALIST \(109\)](#) is TRUE

### 2.2.3. Rejected records

Once a file has finished processing the results of the upload can be checked on the “Upload” screen (see [Appendix A](#)). The data for each individual record is saved as a whole. This means that if one data item fails validation all the submitted changes for the individual record are rejected. A count of those records in the file that passed validation will appear in the corresponding column headed “Successes”; a count of those which failed in the column headed “Failures”.

For those records which failed validation, the reasons for failure can be viewed by clicking on the number displayed in the “Failures” column. This link will open an Upload Summary (see [Appendix B](#)) in a separate browser window. The summary lists for each unsuccessful record all the reasons why the record failed. A record may be rejected for multiple reasons so the number of reasons displayed may exceed the count displayed on the Upload screen. The NHS number of the individual is displayed together with the reason for rejecting the record. Clicking on the NHS Number will open a further browser window providing personal information about the patient. This link may prove useful if the record has failed validation because the patient could not be matched using the data provided in the upload file.

When investigating records which have failed validation it is important to remember that the cause of the problem may not be apparent in the file you have submitted. As explained [above](#) the data provided in the uploaded record is combined with the existing data for the record. The record subjected to validation is a combination of stored data and uploaded data (where any non-null value in the uploaded data replaces the corresponding existing value). If the cause of the rejection is not obvious in the uploaded data, users may find it necessary to view the patient record on screen to try and resolve the problem.

### 2.2.4. Redundant data items

Changes requested as part of Phase 2 Release 1 mean that certain data items are now redundant. To minimise disruption to data collection by users these items will retain their place in the upload file but will be marked in this specification as redundant. Data can be submitted for any redundant item but it will not be imported to the LUCADA database. Alternatively the data item can be left blank (“”) and will be ignored by subsequent processing. Validation associated with any redundant item will be suppressed.

## 2.2.5. Data Items (Upload)

Field No.	NCDS v4.5	NCDS Item Name (v3.0)	Permitted values (in bold)
0.	1.1	NHS NUMBER	Format (10N). 10 digit numeric
1.	1.6	PATIENT FORENAME OR PERSONAL NAME	The patient's forenames
2.	1.5	PATIENT FAMILY OR SURNAME	The patient's surname
3.	1.10	BIRTH DATE	Date: (format CCYY-MM-DD)
4.	1.9	SEX	<ul style="list-style-type: none"> <li>• <b>1</b> (MALE)</li> <li>• <b>2</b> (FEMALE)</li> <li>• <b>0</b> (UNKNOWN)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
5.	DERIVED	Age at time of diagnosis	Age (numeric, whole years). This is a derived field.
6.	1.8	POSTCODE OF USUAL ADDRESS (AT DIAGNOSIS)	The patient's postcode
7.	1.3	ORGANISATION CODE (CODE OF PROVIDER)	
8.	1.4	CARE SPELL IDENTIFIER	Numeric
9.	2.1	SOURCE OF REFERRAL (FOR CANCER)	<ul style="list-style-type: none"> <li>• <b>01</b> (FOLLOWING AN EMERGENCY ADMISSION)</li> <li>• <b>02</b> (FOLLOWING A DOMICILIARY VISIT)</li> <li>• <b>03</b> (REFERRAL FROM GP)</li> <li>• <b>05</b> (REFERRAL FROM A CONSULTANT OTHER THAN IN AN A&amp;E DEPARTMENT)</li> <li>• <b>06</b> (SELF-REFERRAL)</li> <li>• <b>08</b> (OTHER SOURCE OF REFERRAL)</li> <li>• <b>10</b> (FOLLOWING A&amp;E ATTENDANCE)</li> <li>• <b>92</b> (GENERAL DENTAL PRACTITIONER)</li> <li>• <b>93</b> (COMMUNITY DENTAL SERVICE)</li> <li>• <b>99</b> (NOT KNOWN)</li> </ul>
10.	2.5	CANCER REFERRAL DECISION DATE	Date: (format CCYY-MM-DD)
11.	2.9	DATE FIRST SEEN	Date: (format CCYY-MM-DD)
12.	1.3	SITE CODE OF PLACE FIRST SEEN	A valid 5 digit OCS site code
13.	L24	LUNG CANCER SPECIALIST REFERRAL DATE	Date: (format CCYY-MM-DD)
14.	4.1	DIAGNOSIS DATE (CANCER)	Date: (format CCYY-MM-DD)
15.	1.3	SITE CODE (DIAGNOSIS)	A valid 5 digit OCS site code

<p><b>16.</b></p>	<p>4.2</p>	<p>PRIMARY DIAGNOSIS (ICD)</p>	<ul style="list-style-type: none"> <li>• <b>C33</b> (TRACHEA)</li> <li>• <b>C34</b> (MALIGNANT NEOPLASM OF BRONCHUS OR LUNG)</li> <li>• <b>C34.0</b> (MAIN BRONCHUS, CARINA, HILUS OF LUNG)</li> <li>• <b>C34.1</b> (UPPER LOBE, BRONCHUS OR LUNG (INCLUDING PANCOAST))</li> <li>• <b>C34.2</b> (MIDDLE LOBE / LINGULAR, BRONCHUS OR LUNG)</li> <li>• <b>C34.3</b> (LOWER LOBE, BRONCHUS OR LUNG)</li> <li>• <b>C34.8</b> (OVERLAPPING LESION OF BRONCHUS AND LUNG)</li> <li>• <b>C34.9</b> (BRONCHUS OR LUNG, UNSPECIFIED)</li> <li>• <b>C38</b> (MALIGNANT NEOPLASM OF HEART, MEDIASTINUM AND PLEURA)</li> <li>• <b>C38.3</b> (MEDIASTINUM, PART UNSPECIFIED)</li> <li>• <b>C38.4</b> (PLEURA)</li> <li>• <b>C38.8</b> (OVERLAPPING LESION OF HEART, MEDIASTINUM AND PLEURA)</li> <li>• <b>C45</b> (MESOTHELIOMA)</li> <li>• <b>C45.0</b> (MESOTHELIOMA OF PLEURA)</li> </ul>
<p><b>17.</b></p>	<p>4.3</p>	<p>TUMOUR LATERALITY</p>	<ul style="list-style-type: none"> <li>• <b>B</b> (BILATERAL)</li> <li>• <b>L</b> (LEFT)</li> <li>• <b>M</b> (MIDLINE)</li> <li>• <b>R</b> (RIGHT)</li> <li>• <b>8</b> (NOT APPLICABLE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>

18.	4.4	BASIS OF DIAGNOSIS (CANCER)	<ul style="list-style-type: none"> <li>• 0 (DEATH CERTIFICATE)</li> <li>• 1 (CLINICAL)</li> <li>• 2 (CLINICAL INVESTIGATION)</li> <li>• 4 (SPECIFIC TUMOUR MARKERS)</li> <li>• 5 (CYTOLOGY)</li> <li>• 6 (HISTOLOGY OF A METASTASIS)</li> <li>• 7 (HISTOLOGY OF A PRIMARY TUMOUR)</li> <li>• 9 (UNKNOWN)</li> </ul>
19.	6.1	T CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> </ul>
20.	6.3	N CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> </ul>
21.	6.5	M CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> </ul>
22.	6.2	STAGING CERTAINTY FACTOR (T CATEGORY) (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
23.	6.4	STAGING CERTAINTY FACTOR (N CATEGORY) (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
24.	6.6	STAGING CERTAINTY FACTOR (M CATEGORY) (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
25.	6.7	TNM CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• IA</li> <li>• IB</li> <li>• IIA</li> <li>• IIB</li> <li>• IIIA</li> <li>• IIIB</li> <li>• IV</li> <li>• OCCULT CARCINOMA</li> </ul>

26.	4.5	HISTOLOGY (SNOMED)	<ul style="list-style-type: none"> <li>• <b>M8010/2</b> (CARCINOMA IN SITU)</li> <li>• <b>M8010/6</b> (SECONDARY CARCINOMA)</li> <li>• <b>M8012/3</b> (LARGE CELL CARCINOMA NOS)</li> <li>• <b>M8013/3</b> (LARGE CELL NEUROENDOCRINE (ICD-O-3))</li> <li>• <b>M8020/3</b> (LARGE CELL – UNDIFFERENTIATED)</li> <li>• <b>M8041/3</b> (SMALL CELL CARCINOMA)</li> <li>• <b>M8046/3</b> (NON-SMALL CELL CARCINOMA (ICD-O-3))</li> <li>• <b>M8070/3</b> (SQUAMOUS CELL CARCINOMA NOS)</li> <li>• <b>M8140/3</b> (ADENOCARCINOMA NOS)</li> <li>• <b>M8240/3</b> (CARCINOID NOS)</li> <li>• <b>M8250/3</b> (BRONCHIO-ALVEOLAR CELL CARCINOMA)</li> <li>• <b>M8940/3</b> (MIXED TUMOUR)</li> <li>• <b>M8980/3</b> (CARCINOSARCOMA NOS)</li> <li>• <b>M9050/3</b> (MALIGNANT MESOTHELIOMA (NOS))</li> <li>• <b>M9051/3</b> (MESOTHELIOMA (SARCOMATOID) ICD-O-3)</li> <li>• <b>M9052/3</b> (MESOTHELIOMA (EPITHELIOID))</li> <li>• <b>M9053/3</b> (BIPHASIC MESOTHELIOMA)</li> <li>• <b>M9999/9</b> (OTHER)</li> </ul>
27.	6.9	SITE-SPECIFIC STAGING CLASSIFICATION	<ul style="list-style-type: none"> <li>• <b>1</b> (LIMITED DISEASE)</li> <li>• <b>2</b> (EXTENSIVE DISEASE)</li> <li>• <b>X</b> (UNKNOWN)</li> </ul>
28.	5.1	MDT DISCUSSION INDICATOR	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
29.	5.2	MULTIDISCIPLINARY TEAM DISCUSSION DATE	Date: (format CCYY-MM-DD)
30.	5.3	CARE PLAN AGREED DATE (Redundant P2R1)	Date: (format CCYY-MM-DD)

31.	5.5	CANCER CARE PLAN INTENT	<ul style="list-style-type: none"> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NO SPECIFIC ANTI-CANCER TREATMENT)</li> <li>• <b>P</b> (PALLIATIVE ANTI-CANCER)</li> <li>• <b>S</b> (SUPPORTING TREATMENT)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
32.	L7	<i>Is there significant co-morbidity? (Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
33.	L8	<i>Date co-morbidity recorded (Redundant P2R1)</i>	Date: (format CCYY-MM-DD)
34.	L4	<i>COPD (Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
35.	L10	Dementia/cerebrovascular disease	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
36.	L9	Cardiovascular disease	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
37.	L11	Renal failure	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
38.	L12	Other malignancy	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
39.	L13	Severe weight loss	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
40.	L14	Other significant co-morbidity	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
41.	L5	FEV1 ABSOLUTE AMOUNT	Format (99.99) Up to 2 decimal places (0.1 to 10.00 inclusive)
42.	L6	FEV1 PERCENTAGE	Format (999) (1 to 150 inclusive)
43.	5.10	PERFORMANCE STATUS (ADULT)	<ul style="list-style-type: none"> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
44.	7.1	SITE CODE (OF SURGERY)	A valid 5 digit OCS site code
45.	7.5	DECISION TO TREAT DATE (SURGERY)	Date: (format CCYY-MM-DD)
46.	7.9	PROCEDURE DATE (SURGERY)	Date: (format CCYY-MM-DD)

47.	7.10	PRIMARY PROCEDURE (OPCS)	<ul style="list-style-type: none"> <li>• <b>E44.1</b> (CARINAL RESECTION)</li> <li>• <b>E54.1</b> (PNEUMONECTOMY)</li> <li>• <b>E54.2</b> (BILOBECTOMY)</li> <li>• <b>E54.3</b> (LOBECTOMY)</li> <li>• <b>E54.4A</b> (WEDGE RESECTION OF LESION OF LUNG (SEGMENT))</li> <li>• <b>E54.8A</b> (MULTIPLE WEDGES RESECTED)</li> <li>• <b>E54.8B</b> (SLEEVE RESECTION)</li> <li>• <b>E54.8 +T01</b> (LUNG RESECTION WITH RESECTION OF CHEST WALL (NOT IDENTIFYING WHICH LOBE RESECTION))</li> <li>• <b>E55.4B</b> (SEGMENTAL RESECTION)</li> <li>• <b>E57.4</b> (OPEN OPERATION ON LUNG (OPEN AND CLOSE) (INCISION OF LUNG NEC))</li> <li>• <b>E57.8</b> (OTHER OPEN OPERATION ON LUNG)</li> <li>• <b>01</b> (EXTRAPLEURAL PNEUMONECTOMY)</li> <li>• <b>02</b> (DEBULKING PLEURECTOMY)</li> <li>• <b>03</b> (PLEURODESIS)</li> </ul>
48.	L22	<i>Did patient have mediastinoscopy/mediastinotomy? (Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
49.	L15	EXCISION MARGIN	<ul style="list-style-type: none"> <li>• <b>X</b> (RX)</li> <li>• <b>0</b> (R0)</li> <li>• <b>1</b> (R1)</li> <li>• <b>2</b> (R2)</li> </ul>
50.	8.16	T CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> </ul>
51.	8.17	N CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> </ul>
52.	8.18	M CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> </ul>

53.	L16	Certainty factor - pathological stage T value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
54.	L17	Certainty factor - pathological stage N value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
55.	L18	Certainty factor - pathological stage M value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
56.	8.19	TNM CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• IA</li> <li>• IB</li> <li>• IIA</li> <li>• IIB</li> <li>• IIIA</li> <li>• IIIB</li> <li>• IV</li> <li>• OCCULT CARCINOMA</li> </ul>
57.	9.1	SITE CODE (OF ANTI- CANCER DRUG TREATMENT)	A valid 5 digit OCS site code
58.	9.4	DECISION TO TREAT DATE (ANTI-CANCER DRUG REGIMEN)	Date: (format CCYY-MM-DD)
59.	9.10	START DATE (ANTI- CANCER DRUG REGIMEN)	Date: (format CCYY-MM-DD)
60.	9.8	DRUG TREATMENT INTENT (Redundant)	<ul style="list-style-type: none"> <li>• A (ADJUVANT)</li> <li>• C (CURATIVE)</li> <li>• N (NEOADJUVANT)</li> <li>• P (PALLIATIVE)</li> <li>• 9 (UNKNOWN)</li> </ul>
61.	L19	LIKELY TO RECEIVE PROPHYLACTIC CRANIAL IRRADIATION ? (Redundant P2R1)	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
62.	10.1	SITE CODE (OF TELETHERAPY)	A valid 5 digit OCS site code
63.	10.3	DECISION TO TREAT DATE (TELETHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
64.	10.6	CANCER TREATMENT INTENT (Redundant)	<ul style="list-style-type: none"> <li>• A (ADJUVANT)</li> <li>• C (CURATIVE)</li> <li>• N (NEOADJUVANT)</li> <li>• P (PALLIATIVE)</li> <li>• 9 (UNKNOWN)</li> </ul>

65.	10.7	RADIOTHERAPY ANATOMICAL TREATMENT SITE	<ul style="list-style-type: none"> <li>• <b>Z01.9</b> (TISSUE OF BRAIN (NEC))</li> <li>• <b>Z24.3</b> (TRACHEA)</li> <li>• <b>Z24.6</b> (LUNG AND MEDIASTINUM)</li> <li>• <b>Z24.7</b> (LUNG AND MEDIASTINUM)</li> <li>• <b>Z50.9</b> (SKIN OF OTHER (NEC))</li> <li>• <b>Z52.9</b> (CHEST WALL (NEC))</li> <li>• <b>Z87.1</b> (BONE (NEC))</li> <li>• <b>Z92.9</b> (OTHER REGION OF BODY (NEC))</li> <li>• <b>01</b> (MESOTHELIOMA DRAIN SITE)</li> <li>•</li> </ul>
66.	10.8	START DATE (TELEOTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
67.	11.1	SITE CODE (OF BRACHYTHERAPY)	A valid 5 digit OCS site code
68.	11.3	DECISION TO TREAT DATE (BRACHYTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
69.	11.9	START DATE (BRACHYTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
70.	12.n	SITE CODE (SPECIALIST PALLIATIVE TREATMENT COURSE)	A valid 5 digit OCS site code
71.	12.n	DECISION TO TREAT DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)	Date: (format CCYY-MM-DD)
72.	12.n	START DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)	Date: (format CCYY-MM-DD)
73.	L25	SITE CODE (ACTIVE MONITORING)	A valid 5 digit OCS site code
74.	16.9	DECISION TO TREAT DATE (ACTIVE MONITORING)	Date: (format CCYY-MM-DD)
75.	8.3	INVESTIGATION RESULT DATE	Date: (format CCYY-MM-DD)

76.	8.10	HISTOLOGY (SNOMED)	<ul style="list-style-type: none"> <li>• <b>M8010/2</b> (CARCINOMA IN SITU)</li> <li>• <b>M8010/6</b> (SECONDARY CARCINOMA)</li> <li>• <b>M8012/3</b> (LARGE CELL CARCINOMA NOS)</li> <li>• <b>M8013/3</b> (LARGE CELL NEUROENDOCRINE (ICD-O-3))</li> <li>• <b>M8020/3</b> (LARGE CELL – UNDIFFERENTIATED)</li> <li>• <b>M8041/3</b> (SMALL CELL CARCINOMA)</li> <li>• <b>M8046/3</b> (NON-SMALL CELL CARCINOMA (ICD-O-3))</li> <li>• <b>M8070/3</b> (SQUAMOUS CELL CARCINOMA NOS)</li> <li>• <b>M8140/3</b> (ADENOCARCINOMA NOS)</li> <li>• <b>M8240/3</b> (CARCINOID NOS)</li> <li>• <b>M8250/3</b> (BRONCHIO-ALVEOLAR CELL CARCINOMA)</li> <li>• <b>M8940/3</b> (MIXED TUMOUR)</li> <li>• <b>M8980/3</b> (CARCINOSARCOMA NOS)</li> <li>• <b>M9050/3</b> (MALIGNANT MESOTHELIOMA (NOS))</li> <li>• <b>M9052/3</b> (MESOTHELIOMA (EPITHELIOID))</li> <li>• <b>M9051/3</b> (MESOTHELIOMA (SARCOMATOID) ICD-O-3)</li> <li>• <b>M9053/3</b> (BIPHASIC MESOTHELIOMA)</li> <li>• <b>M9999/9</b> (OTHER)</li> </ul>
77.	L23	POST TREATMENT: SITE SPECIFIC CLASSIFICATION	<ul style="list-style-type: none"> <li>• <b>1</b> (LIMITED DISEASE)</li> <li>• <b>2</b> (EXTENSIVE DISEASE)</li> <li>• <b>X</b> (UNKNOWN)</li> </ul>
78.	13.1	PATIENT TRIAL STATUS (CANCER)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
79.	15.1	DEATH DATE	Date: (format CCYY-MM-DD)
80.	L20	DEATH – WAS DEATH RELATED TO TREATMENT	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
81.	14.7	TREATMENT MORBIDITY TYPE (CANCER)	<ul style="list-style-type: none"> <li>• <b>1</b> (SURGERY)</li> <li>• <b>2</b> (CHEMOTHERAPY)</li> <li>• <b>3</b> (RADIOTHERAPY)</li> <li>• <b>4</b> (COMBINATION)</li> </ul>

82.	L21	CONFIRM IF PATIENT RECEIVED PROPHYLACTIC CRANIAL IRRADIATION	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
83.	L26	RADIOTHERAPY TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• <b>01</b> (CURATIVE - RADICAL RT)</li> <li>• <b>02</b> (CURATIVE - CHART/CHARTWEL)</li> <li>• <b>03</b> (PART OF CHEMO/RT TREATMENT PLAN)</li> <li>• <b>04</b> (ADJUVANT FOLLOWING SURGICAL TREATMENT)</li> <li>• <b>05</b> (PALLIATIVE RADIOTHERAPY)</li> </ul>
84.	L27	CHEMOTHERAPY TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• <b>01</b> (CHEMOTHERAPY ALONE)</li> <li>• <b>02</b> (NEO-ADJUVANT CHEMOTHERAPY BEFORE SURGERY)</li> <li>• <b>03</b> (PART OF CHEMO/RT TREATMENT PLAN)</li> <li>• <b>04</b> (ADJUVANT CHEMOTHERAPY POST SURGERY)</li> <li>• <b>05</b> (INDUCTION CHEMOTHERAPY TO DOWN STAGE BEFORE SURGERY)</li> </ul>
85.	L28	TREATMENT PLAN TYPE	<ul style="list-style-type: none"> <li>• <b>01</b> (SINGLE MODALITY)</li> <li>• <b>02</b> (MULTIPLE MODALITY)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
86.	L29	SUGGESTED CANCER TREATMENT PLAN	<ul style="list-style-type: none"> <li>• <b>01</b> (SURGERY)</li> <li>• <b>02</b> (TELETHERAPY (RADIOTHERAPY))</li> <li>• <b>03</b> (CHEMOTHERAPY)</li> <li>• <b>04</b> (BRACHYTHERAPY)</li> <li>• <b>05</b> (PALLIATIVE CARE)</li> <li>• <b>06</b> (ACTIVE MONITORING)</li> <li>• <b>07</b> (SEQUENTIAL CHEMOTHERAPY AND RADIOTHERAPY)</li> <li>• <b>08</b> (CONCURRENT CHEMOTHERAPY AND RADIOTHERAPY)</li> <li>• <b>09</b> (INDUCTION CHEMOTHERAPY TO DOWN STAGE BEFORE SURGERY)</li> <li>• <b>10</b> (NEO-ADJUVANT CHEMOTHERAPY AND SURGERY)</li> <li>• <b>11</b> (SURGERY FOLLOWED BY ADJUVANT CHEMOTHERAPY)</li> </ul>

87.	L30	ORIGINAL TREATMENT PLAN CARRIED OUT	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
88.	L31	ORIGINAL TREATMENT PLAN FAILURE REASON	<ul style="list-style-type: none"> <li>• 01 (CANCER PROGRESSED THROUGH TREATMENT SUCH THAT A NEW TREATMENT PLAN REQUIRED)</li> <li>• 02 (PATIENT CHOICE)</li> <li>• 03 (PATIENT DIED)</li> <li>• 04 (TREATMENT TOXICITY)</li> <li>• 05 (DISEASE PROGRESSION)</li> </ul>
89.	L32	REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT	<ul style="list-style-type: none"> <li>• 01 (REFUSED)</li> <li>• 03 (CO-MORBIDITY PRECLUDING TREATMENT)</li> <li>• 06 (DIED)</li> <li>• L4 (COPD)</li> </ul>
90.	3.3(2A or 2B)	CT SCAN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
91.	3.2	DATE OF CT SCAN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
92.	3.3(4)	PET OR PET/CT SCAN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
93.	3.2	DATE OF PET OR PET/CT SCAN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
94.	L33	BRONCHOSCOPY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
95.	L34	DATE OF BRONCHOSCOPY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
96.	L35	DIAGNOSTIC BIOPSY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
97.	L36	DATE OF DIAGNOSTIC BIOPSY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
98.	L37	CT GUIDED BIOPSY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
99.	L38	DATE OF CT GUIDED BIOPSY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
100.	L39	PALLIATIVE CARE.PROVIDER TYPE	<ul style="list-style-type: none"> <li>• 01 (HOSPITAL)</li> <li>• 02 (COMMUNITY)</li> </ul>
101.	L40	PALLIATIVE CARE.COMMUNITY PROVIDER TYPE	<ul style="list-style-type: none"> <li>• 01 (HOSPICE)</li> <li>• 02 (NURSING HOME)</li> <li>• 03 (HOME CARE)</li> <li>• 08 (OTHER)</li> <li>• 9 (UNKNOWN)</li> </ul>
102.	L41	PALLIATIVE CARE.INTERVENTIONAL TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>

103.	L42	DATE INTERVENTIONAL TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
104.	L43	STAGING PROCEDURE PERFORMED	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
105.	L22	STAGING PROCEDURE MEDIASTINOSCOPY MEDIASTINOTOMY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
106.	L44	STAGING PROCEDURE PERFORMED FNA	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
107.	L45	STAGING PROCEDURE OTHER STAGING	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
108.	L46	STAGING PROCEDURE UNKNOWN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
109.	L47	PATIENT ASSESSED BY A LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>
110.	L48	DATE FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
111.	L49	HOW WAS PATIENT FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• 1 (IN CLINIC)</li> <li>• 2 (HOME VISIT)</li> <li>• 3 (WARD VISIT)</li> <li>• 4 (TELEPHONE)</li> <li>• 8 (OTHER)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>
112.	L50	AT WHAT STAGE(S) IN THE PATIENT PATHWAY DID ASSESSMENT BY LUNG CANCER NURSE SPECIALIST OCCUR	<ul style="list-style-type: none"> <li>• 1 (BEFORE DIAGNOSIS)</li> <li>• 2 (WHEN PATIENT RECEIVED DIAGNOSIS ONLY)</li> <li>• 3 (AFTER DIAGNOSIS)</li> <li>• 4 (BEFORE AND AFTER DIAGNOSIS)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>
113.	L51	LUNG CANCER NURSE SPECIALIST PRESENT WHEN PATIENT RECEIVED DIAGNOSIS	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>

### 2.2.6. Data Items (Single Organisation Download)

This is the standard, default download for subscribing organisations providing data via upload or screen input.

Field No.	NCDS v4.5	NCDS Item Name (v3.0)	Permitted values (in bold)
0.		LUCADA Unique Identifier	Numeric
1.		DATE/TIME of Download	DD/MM/YYYY HH.MM

2.	1.1	NHS NUMBER	Format (10N). 10 digit numeric
3.	1.9	SEX	<ul style="list-style-type: none"> <li>• 1 (MALE)</li> <li>• 2 (FEMALE)</li> <li>• 0 (UNKNOWN)</li> <li>• 9 (UNKNOWN)</li> </ul>
4.	DERIVED	Age at time of diagnosis	Age (numeric, whole years). This is a derived field.
5.	1.8	POSTCODE OF USUAL ADDRESS (AT DIAGNOSIS)	The patient's postcode
6.	1.3	ORGANISATION CODE (CODE OF PROVIDER)	
7.	1.4	CARE SPELL IDENTIFIER	Numeric
8.	2.1	SOURCE OF REFERRAL (FOR CANCER)	<ul style="list-style-type: none"> <li>• 01 (FOLLOWING AN EMERGENCY ADMISSION)</li> <li>• 02 (FOLLOWING A DOMICILIARY VISIT)</li> <li>• 03 (REFERRAL FROM GP)</li> <li>• 05 (REFERRAL FROM A CONSULTANT OTHER THAN IN AN A&amp;E DEPARTMENT)</li> <li>• 06 (SELF-REFERRAL)</li> <li>• 08 (OTHER SOURCE OF REFERRAL)</li> <li>• 10 (FOLLOWING A&amp;E ATTENDANCE)</li> <li>• 92 (GENERAL DENTAL PRACTITIONER)</li> <li>• 93 (COMMUNITY DENTAL SERVICE)</li> <li>• 99 (NOT KNOWN)</li> </ul>
9.	2.5	CANCER REFERRAL DECISION DATE	Date: (format CCYY-MM-DD)
10.	2.9	DATE FIRST SEEN	Date: (format CCYY-MM-DD)
11.	1.3	SITE CODE OF PLACE FIRST SEEN	A valid 5 digit OCS site code
12.	L24	LUNG CANCER SPECIALIST REFERRAL DATE	Date: (format CCYY-MM-DD)
13.	4.1	DIAGNOSIS DATE (CANCER)	Date: (format CCYY-MM-DD)
14.	1.3	SITE CODE (DIAGNOSIS)	A valid 5 digit OCS site code

<p>15.</p>	<p>4.2</p>	<p>PRIMARY DIAGNOSIS (ICD)</p>	<ul style="list-style-type: none"> <li>• <b>C33</b> (TRACHEA)</li> <li>• <b>C34</b> (MALIGNANT NEOPLASM OF BRONCHUS OR LUNG)</li> <li>• <b>C34.0</b> (MAIN BRONCHUS, CARINA, HILUS OF LUNG)</li> <li>• <b>C34.1</b> (UPPER LOBE, BRONCHUS OR LUNG (INCLUDING PANCOAST))</li> <li>• <b>C34.2</b> (MIDDLE LOBE / LINGULAR, BRONCHUS OR LUNG)</li> <li>• <b>C34.3</b> (LOWER LOBE, BRONCHUS OR LUNG)</li> <li>• <b>C34.8</b> (OVERLAPPING LESION OF BRONCHUS AND LUNG)</li> <li>• <b>C34.9</b> (BRONCHUS OR LUNG, UNSPECIFIED)</li> <li>• <b>C38</b> (MALIGNANT NEOPLASM OF HEART, MEDIASTINUM AND PLEURA)</li> <li>• <b>C38.3</b> (MEDIASTINUM, PART UNSPECIFIED)</li> <li>• <b>C38.4</b> (PLEURA)</li> <li>• <b>C38.8</b> (OVERLAPPING LESION OF HEART, MEDIASTINUM AND PLEURA)</li> <li>• <b>C45</b> (MESOTHELIOMA)</li> <li>• <b>C45.0</b> (MESOTHELIOMA OF PLEURA)</li> </ul>
------------	------------	--------------------------------	---

16.	4.3	TUMOUR LATERALITY	<ul style="list-style-type: none"> <li>• B (BILATERAL)</li> <li>• L (LEFT)</li> <li>• M (MIDLINE)</li> <li>• R (RIGHT)</li> <li>• 8 (NOT APPLICABLE)</li> <li>• 9 (UNKNOWN)</li> </ul>
17.	4.4	BASIS OF DIAGNOSIS (CANCER)	<ul style="list-style-type: none"> <li>• 0 (DEATH CERTIFICATE)</li> <li>• 1 (CLINICAL)</li> <li>• 2 (CLINICAL INVESTIGATION)</li> <li>• 4 (SPECIFIC TUMOUR MARKERS)</li> <li>• 5 (CYTOLOGY)</li> <li>• 6 (HISTOLOGY OF A METASTASIS)</li> <li>• 7 (HISTOLOGY OF A PRIMARY TUMOUR)</li> <li>• 9 (UNKNOWN)</li> </ul>
18.	6.1	T CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> </ul>
19.	6.3	N CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> </ul>
20.	6.5	M CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> </ul>
21.	6.2	STAGING CERTAINTY FACTOR (T CATEGORY) <i>(Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
22.	6.4	STAGING CERTAINTY FACTOR (N CATEGORY) <i>(Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
23.	6.6	STAGING CERTAINTY FACTOR (M CATEGORY) <i>(Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>

24.	6.7	TNM CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• IA</li> <li>• IB</li> <li>• IIA</li> <li>• IIB</li> <li>• IIIA</li> <li>• IIIB</li> <li>• IV</li> <li>• OCCULT CARCINOMA</li> </ul>
25.	4.5	HISTOLOGY (SNOMED)	<ul style="list-style-type: none"> <li>• <b>M8010/2</b> (CARCINOMA IN SITU)</li> <li>• <b>M8010/6</b> (SECONDARY CARCINOMA)</li> <li>• <b>M8012/3</b> (LARGE CELL CARCINOMA NOS)</li> <li>• <b>M8013/3</b> (LARGE CELL NEUROENDOCRINE (ICD-O-3))</li> <li>• <b>M8020/3</b> (LARGE CELL – UNDIFFERENTIATED)</li> <li>• <b>M8041/3</b> (SMALL CELL CARCINOMA)</li> <li>• <b>M8046/3</b> (NON-SMALL CELL CARCINOMA (ICD-O-3))</li> <li>• <b>M8070/3</b> (SQUAMOUS CELL CARCINOMA NOS)</li> <li>• <b>M8140/3</b> (ADENOCARCINOMA NOS)</li> <li>• <b>M8240/3</b> (CARCINOID NOS)</li> <li>• <b>M8250/3</b> (BRONCHIO-ALVEOLAR CELL CARCINOMA)</li> <li>• <b>M8940/3</b> (MIXED TUMOUR)</li> <li>• <b>M8980/3</b> (CARCINOSARCOMA NOS)</li> <li>• <b>M9050/3</b> (MALIGNANT MESOTHELIOMA (NOS))</li> <li>• <b>M9051/3</b> (MESOTHELIOMA (SARCOMATOID) ICD-O-3)</li> <li>• <b>M9052/3</b> (MESOTHELIOMA (EPITHELIOID))</li> <li>• <b>M9053/3</b> (BIPHASIC MESOTHELIOMA)</li> <li>• <b>M9999/9</b> (OTHER)</li> </ul>
26.	6.9	SITE-SPECIFIC STAGING CLASSIFICATION	<ul style="list-style-type: none"> <li>• <b>1</b> (LIMITED DISEASE)</li> <li>• <b>2</b> (EXTENSIVE DISEASE)</li> <li>• <b>X</b> (UNKNOWN)</li> </ul>
27.	5.1	MDT DISCUSSION INDICATOR	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
28.	5.2	MULTIDISCIPLINARY TEAM DISCUSSION DATE	Date: (format CCYY-MM-DD)

29.	5.3	CARE PLAN AGREED DATE (Redundant P2R1)	Date: (format CCYY-MM-DD)
30.	5.5	CANCER CARE PLAN INTENT	<ul style="list-style-type: none"> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NO SPECIFIC ANTI-CANCER TREATMENT)</li> <li>• <b>P</b> (PALLIATIVE ANTI-CANCER)</li> <li>• <b>S</b> (SUPPORTING TREATMENT)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
31.	L7	Is there significant co-morbidity? (Redundant P2R1)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
32.	L8	Date co-morbidity recorded (Redundant P2R1)	Date: (format CCYY-MM-DD)
33.	L4	COPD (Redundant P2R1)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
34.	L10	Dementia/cerebrovascular disease	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
35.	L9	Cardiovascular disease	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
36.	L11	Renal failure	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
37.	L12	Other malignancy	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
38.	L13	Severe weight loss	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
39.	L14	Other significant co-morbidity	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
40.	L5	FEV1 ABSOLUTE AMOUNT	Format (99.99) Up to 2 decimal places (0.1 to 10.00 inclusive)
41.	L6	FEV1 PERCENTAGE	Format (999) (1 to 150 inclusive)
42.	5.10	PERFORMANCE STATUS (ADULT)	<ul style="list-style-type: none"> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
43.	7.1	SITE CODE (OF SURGERY)	A valid 5 digit OCS site code
44.	7.5	DECISION TO TREAT DATE (SURGERY)	Date: (format CCYY-MM-DD)
45.	7.9	PROCEDURE DATE (SURGERY)	Date: (format CCYY-MM-DD)

46.	7.10	PRIMARY PROCEDURE (OPCS)	<ul style="list-style-type: none"> <li>• <b>E44.1</b> (CARINAL RESECTION)</li> <li>• <b>E54.1</b> (PNEUMONECTOMY)</li> <li>• <b>E54.2</b> (BILOBECTOMY)</li> <li>• <b>E54.3</b> (LOBECTOMY)</li> <li>• <b>E54.4A</b> (WEDGE RESECTION OF LESION OF LUNG (SEGMENT))</li> <li>• <b>E54.8A</b> (MULTIPLE WEDGES RESECTED)</li> <li>• <b>E54.8B</b> (SLEEVE RESECTION)</li> <li>• <b>E54.8 +T01</b> (LUNG RESECTION WITH RESECTION OF CHEST WALL (NOT IDENTIFYING WHICH LOBE RESECTION))</li> <li>• <b>E55.4B</b> (SEGMENTAL RESECTION)</li> <li>• <b>E57.4</b> (OPEN OPERATION ON LUNG (OPEN AND CLOSE) (INCISION OF LUNG NEC))</li> <li>• <b>E57.8</b> (OTHER OPEN OPERATION ON LUNG)</li> <li>• <b>01</b> (EXTRAPLEURAL PNEUMONECTOMY)</li> <li>• <b>02</b> (DEBULKING PLEURECTOMY)</li> <li>• <b>03</b> (PLEURODESIS)</li> </ul>
47.	L22	<i>Did patient have mediastinoscopy/mediastinotomy? (Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
48.	L15	EXCISION MARGIN	<ul style="list-style-type: none"> <li>• <b>X</b> (RX)</li> <li>• <b>0</b> (R0)</li> <li>• <b>1</b> (R1)</li> <li>• <b>2</b> (R2)</li> </ul>
49.	8.16	T CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> </ul>
50.	8.17	N CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> </ul>
51.	8.18	M CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> </ul>

52.	L16	Certainty factor - pathological stage T value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
53.	L17	Certainty factor - pathological stage N value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
54.	L18	Certainty factor - pathological stage M value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
55.	8.19	TNM CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• IA</li> <li>• IB</li> <li>• IIA</li> <li>• IIB</li> <li>• IIIA</li> <li>• IIIB</li> <li>• IV</li> <li>• OCCULT CARCINOMA</li> </ul>
56.	9.1	SITE CODE (OF ANTI- CANCER DRUG TREATMENT)	A valid 5 digit OCS site code
57.	9.4	DECISION TO TREAT DATE (ANTI-CANCER DRUG REGIMEN)	Date: (format CCYY-MM-DD)
58.	9.10	START DATE (ANTI- CANCER DRUG REGIMEN)	Date: (format CCYY-MM-DD)
59.	9.8	DRUG TREATMENT INTENT	<ul style="list-style-type: none"> <li>• <b>A</b> (ADJUVANT)</li> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NEOADJUVANT)</li> <li>• <b>P</b> (PALLIATIVE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
60.	L19	LIKELY TO RECEIVE PROPHYLACTIC CRANIAL IRRADIATION ? (Redundant P2R1)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
61.	10.1	SITE CODE (OF TELETHERAPY)	A valid 5 digit OCS site code
62.	10.3	DECISION TO TREAT DATE (TELETHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
63.	10.6	CANCER TREATMENT INTENT	<ul style="list-style-type: none"> <li>• <b>A</b> (ADJUVANT)</li> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NEOADJUVANT)</li> <li>• <b>P</b> (PALLIATIVE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>

64.	10.7	RADIOTHERAPY ANATOMICAL TREATMENT SITE	<ul style="list-style-type: none"> <li>• <b>Z01.9</b> (TISSUE OF BRAIN (NEC))</li> <li>• <b>Z24.3</b> (TRACHEA)</li> <li>• <b>Z24.6</b> (LUNG AND MEDIASTINUM)</li> <li>• <b>Z24.7</b> (LUNG AND MEDIASTINUM)</li> <li>• <b>Z50.9</b> (SKIN OF OTHER (NEC))</li> <li>• <b>Z52.9</b> (CHEST WALL (NEC))</li> <li>• <b>Z87.1</b> (BONE (NEC))</li> <li>• <b>Z92.9</b> (OTHER REGION OF BODY (NEC))</li> <li>• <b>01</b> (MESOTHELIOMA DRAIN SITE)</li> <li>•</li> </ul>
65.	10.8	START DATE (TELEOTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
66.	11.1	SITE CODE (OF BRACHYTHERAPY)	A valid 5 digit OCS site code
67.	11.3	DECISION TO TREAT DATE (BRACHYTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
68.	11.9	START DATE (BRACHYTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
69.	12.n	SITE CODE (SPECIALIST PALLIATIVE TREATMENT COURSE)	A valid 5 digit OCS site code
70.	12.n	DECISION TO TREAT DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)	Date: (format CCYY-MM-DD)
71.	12.n	START DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)	Date: (format CCYY-MM-DD)
72.	L25	SITE CODE (ACTIVE MONITORING)	A valid 5 digit OCS site code
73.	16.9	DECISION TO TREAT DATE (ACTIVE MONITORING)	Date: (format CCYY-MM-DD)
74.	8.3	INVESTIGATION RESULT DATE	Date: (format CCYY-MM-DD)

75.	8.10	HISTOLOGY (SNOMED)	<ul style="list-style-type: none"> <li>• <b>M8010/2</b> (CARCINOMA IN SITU)</li> <li>• <b>M8010/6</b> (SECONDARY CARCINOMA)</li> <li>• <b>M8012/3</b> (LARGE CELL CARCINOMA NOS)</li> <li>• <b>M8013/3</b> (LARGE CELL NEUROENDOCRINE (ICD-O-3))</li> <li>• <b>M8020/3</b> (LARGE CELL – UNDIFFERENTIATED)</li> <li>• <b>M8041/3</b> (SMALL CELL CARCINOMA)</li> <li>• <b>M8046/3</b> (NON-SMALL CELL CARCINOMA (ICD-O-3))</li> <li>• <b>M8070/3</b> (SQUAMOUS CELL CARCINOMA NOS)</li> <li>• <b>M8140/3</b> (ADENOCARCINOMA NOS)</li> <li>• <b>M8240/3</b> (CARCINOID NOS)</li> <li>• <b>M8250/3</b> (BRONCHIO-ALVEOLAR CELL CARCINOMA)</li> <li>• <b>M8940/3</b> (MIXED TUMOUR)</li> <li>• <b>M8980/3</b> (CARCINOSARCOMA NOS)</li> <li>• <b>M9050/3</b> (MALIGNANT MESOTHELIOMA (NOS))</li> <li>• <b>M9052/3</b> (MESOTHELIOMA (EPITHELIOD))</li> <li>• <b>M9051/3</b> (MESOTHELIOMA (SARCOMATOID) ICD-O-3)</li> <li>• <b>M9053/3</b> (BIPHASIC MESOTHELIOMA)</li> <li>• <b>M9999/9</b> (OTHER)</li> </ul>
76.	L23	POST TREATMENT: SITE SPECIFIC CLASSIFICATION	<ul style="list-style-type: none"> <li>• <b>1</b> (LIMITED DISEASE)</li> <li>• <b>2</b> (EXTENSIVE DISEASE)</li> <li>• <b>X</b> (UNKNOWN)</li> </ul>
77.	13.1	PATIENT TRIAL STATUS (CANCER)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
78.	15.1	DEATH DATE	Date: (format CCYY-MM-DD)
79.	L20	DEATH – WAS DEATH RELATED TO TREATMENT	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
80.	14.7	TREATMENT MORBIDITY TYPE (CANCER)	<ul style="list-style-type: none"> <li>• <b>1</b> (SURGERY)</li> <li>• <b>2</b> (CHEMOTHERAPY)</li> <li>• <b>3</b> (RADIOTHERAPY)</li> <li>• <b>4</b> (COMBINATION)</li> </ul>

81.	L21	CONFIRM IF PATIENT RECEIVED PROPHYLACTIC CRANIAL IRRADIATION	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
82.	L26	RADIOTHERAPY TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• 01 (CURATIVE - RADICAL RT)</li> <li>• 02 (CURATIVE - CHART/CHARTWEL)</li> <li>• 03 (PART OF CHEMO/RT TREATMENT PLAN)</li> <li>• 04 (ADJUVANT FOLLOWING SURGICAL TREATMENT)</li> <li>• 05 (PALLIATIVE RADIOTHERAPY)</li> </ul>
83.	L27	CHEMOTHERAPY TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• 01 (CHEMOTHERAPY ALONE)</li> <li>• 02 (NEO-ADJUVANT CHEMOTHERAPY BEFORE SURGERY)</li> <li>• 03 (PART OF CHEMO/RT TREATMENT PLAN)</li> <li>• 04 (ADJUVANT CHEMOTHERAPY POST SURGERY)</li> <li>• 05 (INDUCTION CHEMOTHERAPY TO DOWN STAGE BEFORE SURGERY)</li> </ul>
84.	L28	TREATMENT PLAN TYPE	<ul style="list-style-type: none"> <li>• 01 (SINGLE MODALITY)</li> <li>• 02 (MULTIPLE MODALITY)</li> <li>• 9 (UNKNOWN)</li> </ul>
85.	L29	SUGGESTED CANCER TREATMENT PLAN	<ul style="list-style-type: none"> <li>• 01 (SURGERY)</li> <li>• 02 (TELETHERAPY (RADIOTHERAPY))</li> <li>• 03 (CHEMOTHERAPY)</li> <li>• 04 (BRACHYTHERAPY)</li> <li>• 05 (PALLIATIVE CARE)</li> <li>• 06 (ACTIVE MONITORING)</li> <li>• 07 (SEQUENTIAL CHEMOTHERAPY AND RADIOTHERAPY)</li> <li>• 08 (CONCURRENT CHEMOTHERAPY AND RADIOTHERAPY)</li> <li>• 09 (INDUCTION CHEMOTHERAPY TO DOWN STAGE BEFORE SURGERY)</li> <li>• 10 (NEO-ADJUVANT CHEMOTHERAPY AND SURGERY)</li> <li>• 11 (SURGERY FOLLOWED BY ADJUVANT CHEMOTHERAPY)</li> </ul>

86.	L30	ORIGINAL TREATMENT PLAN CARRIED OUT	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
87.	L31	ORIGINAL TREATMENT PLAN FAILURE REASON	<ul style="list-style-type: none"> <li>• 01 (CANCER PROGRESSED THROUGH TREATMENT SUCH THAT A NEW TREATMENT PLAN REQUIRED)</li> <li>• 02 (PATIENT CHOICE)</li> <li>• 03 (PATIENT DIED)</li> <li>• 04 (TREATMENT TOXICITY)</li> <li>• 05 (DISEASE PROGRESSION)</li> </ul>
88.	L32	REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT	<ul style="list-style-type: none"> <li>• 01 (REFUSED)</li> <li>• 03 (CO-MORBIDITY PRECLUDING TREATMENT)</li> <li>• 06 (DIED)</li> <li>• L4 (COPD)</li> </ul>
89.	3.3(2A or 2B)	CT SCAN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
90.	3.2	DATE OF CT SCAN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
91.	3.3(4)	PET OR PET/CT SCAN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
92.	3.2	DATE OF PET OR PET/CT SCAN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
93.	L33	BRONCHOSCOPY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
94.	L34	DATE OF BRONCHOSCOPY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
95.	L35	DIAGNOSTIC BIOPSY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
96.	L36	DATE OF DIAGNOSTIC BIOPSY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
97.	L37	CT GUIDED BIOPSY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
98.	L38	DATE OF CT GUIDED BIOPSY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
99.	L39	PALLIATIVE CARE.PROVIDER TYPE	<ul style="list-style-type: none"> <li>• 01 (HOSPITAL)</li> <li>• 02 (COMMUNITY)</li> </ul>
100.	L40	PALLIATIVE CARE.COMMUNITY PROVIDER TYPE	<ul style="list-style-type: none"> <li>• 01 (HOSPICE)</li> <li>• 02 (NURSING HOME)</li> <li>• 03 (HOME CARE)</li> <li>• 08 (OTHER)</li> <li>• 9 (UNKNOWN)</li> </ul>
101.	L41	PALLIATIVE CARE.INTERVENTIONAL TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>

<b>102.</b>	L42	DATE INTERVENTIONAL TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
<b>103.</b>	L43	STAGING PROCEDURE PERFORMED	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
<b>104.</b>	L22	STAGING PROCEDURE MEDIASTINOSCOPY MEDIASTINOTOMY	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
<b>105.</b>	L44	STAGING PROCEDURE PERFORMED FNA	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
<b>106.</b>	L45	STAGING PROCEDURE OTHER STAGING	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
<b>107.</b>	L46	STAGING PROCEDURE UNKNOWN	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
<b>108.</b>	L47	PATIENT ASSESSED BY A LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> <li>• <b>99</b> (NOT RECORDED)</li> </ul>
<b>109.</b>	L48	DATE FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
<b>110.</b>	L49	HOW WAS PATIENT FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• <b>1</b> (IN CLINIC)</li> <li>• <b>2</b> (HOME VISIT)</li> <li>• <b>3</b> (WARD VISIT)</li> <li>• <b>4</b> (TELEPHONE)</li> <li>• <b>8</b> (OTHER)</li> <li>• <b>9</b> (UNKNOWN)</li> <li>• <b>99</b> (NOT RECORDED)</li> </ul>
<b>111.</b>	L50	AT WHAT STAGE(S) IN THE PATIENT PATHWAY DID ASSESSMENT BY LUNG CANCER NURSE SPECIALIST OCCUR	<ul style="list-style-type: none"> <li>• <b>1</b> (BEFORE DIAGNOSIS)</li> <li>• <b>2</b> (WHEN PATIENT RECEIVED DIAGNOSIS ONLY)</li> <li>• <b>3</b> (AFTER DIAGNOSIS)</li> <li>• <b>4</b> (BEFORE AND AFTER DIAGNOSIS)</li> <li>• <b>9</b> (UNKNOWN)</li> <li>• <b>99</b> (NOT RECORDED)</li> </ul>
<b>112.</b>	L51	LUNG CANCER NURSE SPECIALIST PRESENT WHEN PATIENT RECEIVED DIAGNOSIS	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> <li>• <b>99</b> (NOT RECORDED)</li> </ul>

**2.2.7. Data Items (Download All Organisations - Anonymous)**

This should be the standard, default download for the designated superuser.

Field No.	NCDS v4.5	NCDS Item Name (v3.0)	Permitted values (in bold)
<b>0.</b>		LUCADA Unique Identifier	Numeric

1.		DATE/TIME OF DOWNLOAD	DD/MM/YYYY HH.MM
2.	1.9	SEX	<ul style="list-style-type: none"> <li>• 1 (MALE)</li> <li>• 2 (FEMALE)</li> <li>• 0 (UNKNOWN)</li> <li>• 9 (UNKNOWN)</li> </ul>
3.	DERIVED	Age at time of diagnosis	Age (numeric, whole years). This is a derived field.
4.	1.8	POSTCODE OF USUAL ADDRESS (AT DIAGNOSIS)	The patient's postcode
5.	1.3	ORGANISATION CODE (CODE OF PROVIDER)	
6.	1.4	CARE SPELL IDENTIFIER	Numeric
7.	2.1	SOURCE OF REFERRAL (FOR CANCER)	<ul style="list-style-type: none"> <li>• 01 (FOLLOWING AN EMERGENCY ADMISSION)</li> <li>• 02 (FOLLOWING A DOMICILIARY VISIT)</li> <li>• 03 (REFERRAL FROM GP)</li> <li>• 05 (REFERRAL FROM A CONSULTANT OTHER THAN IN AN A&amp;E DEPARTMENT)</li> <li>• 06 (SELF-REFERRAL)</li> <li>• 08 (OTHER SOURCE OF REFERRAL)</li> <li>• 10 (FOLLOWING A&amp;E ATTENDANCE)</li> <li>• 92 (GENERAL DENTAL PRACTITIONER)</li> <li>• 93 (COMMUNITY DENTAL SERVICE)</li> <li>• 99 (NOT KNOWN)</li> </ul>
8.	2.5	CANCER REFERRAL DECISION DATE	Date: (format CCYY-MM-DD)
9.	2.9	DATE FIRST SEEN	Date: (format CCYY-MM-DD)
10.	1.3	SITE CODE OF PLACE FIRST SEEN	A valid 5 digit OCS site code
11.	L24	LUNG CANCER SPECIALIST REFERRAL DATE	Date: (format CCYY-MM-DD)
12.	4.1	DIAGNOSIS DATE (CANCER)	Date: (format CCYY-MM-DD)
13.	1.3	SITE CODE (DIAGNOSIS)	A valid 5 digit OCS site code

<p>14.</p>	<p>4.2</p>	<p>PRIMARY DIAGNOSIS (ICD)</p>	<ul style="list-style-type: none"> <li>• <b>C33</b> (TRACHEA)</li> <li>• <b>C34</b> (MALIGNANT NEOPLASM OF BRONCHUS OR LUNG)</li> <li>• <b>C34.0</b> (MAIN BRONCHUS, CARINA, HILUS OF LUNG)</li> <li>• <b>C34.1</b> (UPPER LOBE, BRONCHUS OR LUNG (INCLUDING PANCOAST))</li> <li>• <b>C34.2</b> (MIDDLE LOBE / LINGULAR, BRONCHUS OR LUNG)</li> <li>• <b>C34.3</b> (LOWER LOBE, BRONCHUS OR LUNG)</li> <li>• <b>C34.8</b> (OVERLAPPING LESION OF BRONCHUS AND LUNG)</li> <li>• <b>C34.9</b> (BRONCHUS OR LUNG, UNSPECIFIED)</li> <li>• <b>C38</b> (MALIGNANT NEOPLASM OF HEART, MEDIASTINUM AND PLEURA)</li> <li>• <b>C38.3</b> (MEDIASTINUM, PART UNSPECIFIED)</li> <li>• <b>C38.4</b> (PLEURA)</li> <li>• <b>C38.8</b> (OVERLAPPING LESION OF HEART, MEDIASTINUM AND PLEURA)</li> <li>• <b>C45</b> (MESOTHELIOMA)</li> <li>• <b>C45.0</b> (MESOTHELIOMA OF PLEURA)</li> </ul>
------------	------------	--------------------------------	---

<b>15.</b>	4.3	TUMOUR LATERALITY	<ul style="list-style-type: none"> <li>• <b>B</b> (BILATERAL)</li> <li>• <b>L</b> (LEFT)</li> <li>• <b>M</b> (MIDLINE)</li> <li>• <b>R</b> (RIGHT)</li> <li>• <b>8</b> (NOT APPLICABLE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
<b>16.</b>	4.4	BASIS OF DIAGNOSIS (CANCER)	<ul style="list-style-type: none"> <li>• <b>0</b> (DEATH CERTIFICATE)</li> <li>• <b>1</b> (CLINICAL)</li> <li>• <b>2</b> (CLINICAL INVESTIGATION)</li> <li>• <b>4</b> (SPECIFIC TUMOUR MARKERS)</li> <li>• <b>5</b> (CYTOLOGY)</li> <li>• <b>6</b> (HISTOLOGY OF A METASTASIS)</li> <li>• <b>7</b> (HISTOLOGY OF A PRIMARY TUMOUR)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
<b>17.</b>	6.1	T CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> </ul>
<b>18.</b>	6.3	N CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> </ul>
<b>19.</b>	6.5	M CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> </ul>
<b>20.</b>	6.2	STAGING CERTAINTY FACTOR (T CATEGORY) <i>(Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
<b>21.</b>	6.4	STAGING CERTAINTY FACTOR (N CATEGORY) <i>(Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
<b>22.</b>	6.6	STAGING CERTAINTY FACTOR (M CATEGORY) <i>(Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>

23.	6.7	TNM CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• IA</li> <li>• IB</li> <li>• IIA</li> <li>• IIB</li> <li>• IIIA</li> <li>• IIIB</li> <li>• IV</li> <li>• OCCULT CARCINOMA</li> </ul>
24.	4.5	HISTOLOGY (SNOMED)	<ul style="list-style-type: none"> <li>• <b>M8010/2</b> (CARCINOMA IN SITU)</li> <li>• <b>M8010/6</b> (SECONDARY CARCINOMA)</li> <li>• <b>M8012/3</b> (LARGE CELL CARCINOMA NOS)</li> <li>• <b>M8013/3</b> (LARGE CELL NEUROENDOCRINE (ICD-O-3))</li> <li>• <b>M8020/3</b> (LARGE CELL – UNDIFFERENTIATED)</li> <li>• <b>M8041/3</b> (SMALL CELL CARCINOMA)</li> <li>• <b>M8046/3</b> (NON-SMALL CELL CARCINOMA (ICD-O-3))</li> <li>• <b>M8070/3</b> (SQUAMOUS CELL CARCINOMA NOS)</li> <li>• <b>M8140/3</b> (ADENOCARCINOMA NOS)</li> <li>• <b>M8240/3</b> (CARCINOID NOS)</li> <li>• <b>M8250/3</b> (BRONCHIO-ALVEOLAR CELL CARCINOMA)</li> <li>• <b>M8940/3</b> (MIXED TUMOUR)</li> <li>• <b>M8980/3</b> (CARCINOSARCOMA NOS)</li> <li>• <b>M9050/3</b> (MALIGNANT MESOTHELIOMA (NOS))</li> <li>• <b>M9051/3</b> (MESOTHELIOMA (SARCOMATOID) ICD-O-3)</li> <li>• <b>M9052/3</b> (MESOTHELIOMA (EPITHELIOID))</li> <li>• <b>M9053/3</b> (BIPHASIC MESOTHELIOMA)</li> <li>• <b>M9999/9</b> (OTHER)</li> </ul>
25.	6.9	SITE-SPECIFIC STAGING CLASSIFICATION	<ul style="list-style-type: none"> <li>• <b>1</b> (LIMITED DISEASE)</li> <li>• <b>2</b> (EXTENSIVE DISEASE)</li> <li>• <b>X</b> (UNKNOWN)</li> </ul>
26.	5.1	MDT DISCUSSION INDICATOR	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
27.	5.2	MULTIDISCIPLINARY TEAM DISCUSSION DATE	Date: (format CCYY-MM-DD)

28.	5.3	CARE PLAN AGREED DATE (Redundant P2R1)	Date: (format CCYY-MM-DD)
29.	5.5	CANCER CARE PLAN INTENT	<ul style="list-style-type: none"> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NO SPECIFIC ANTI-CANCER TREATMENT)</li> <li>• <b>P</b> (PALLIATIVE ANTI-CANCER)</li> <li>• <b>S</b> (SUPPORTING TREATMENT)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
30.	L7	Is there significant co-morbidity? (Redundant P2R1)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
31.	L8	Date co-morbidity recorded (Redundant P2R1)	Date: (format CCYY-MM-DD)
32.	L4	COPD (Redundant P2R1)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
33.	L10	Dementia/cerebrovascular disease	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
34.	L9	Cardiovascular disease	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
35.	L11	Renal failure	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
36.	L12	Other malignancy	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
37.	L13	Severe weight loss	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
38.	L14	Other significant co-morbidity	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
39.	L5	FEV1 ABSOLUTE AMOUNT	Format (99.99) Up to 2 decimal places (0.1 to 10.00 inclusive)
40.	L6	FEV1 PERCENTAGE	Format (999) (1 to 150 inclusive)
41.	5.10	PERFORMANCE STATUS (ADULT)	<ul style="list-style-type: none"> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
42.	7.1	SITE CODE (OF SURGERY)	A valid 5 digit OCS site code
43.	7.5	DECISION TO TREAT DATE (SURGERY)	Date: (format CCYY-MM-DD)
44.	7.9	PROCEDURE DATE (SURGERY)	Date: (format CCYY-MM-DD)

45.	7.10	PRIMARY PROCEDURE (OPCS)	<ul style="list-style-type: none"> <li>• <b>E44.1</b> (CARINAL RESECTION)</li> <li>• <b>E54.1</b> (PNEUMONECTOMY)</li> <li>• <b>E54.2</b> (BILOBECTOMY)</li> <li>• <b>E54.3</b> (LOBECTOMY)</li> <li>• <b>E54.4A</b> (WEDGE RESECTION OF LESION OF LUNG (SEGMENT))</li> <li>• <b>E54.8A</b> (MULTIPLE WEDGES RESECTED)</li> <li>• <b>E54.8B</b> (SLEEVE RESECTION)</li> <li>• <b>E54.8 +T01</b> (LUNG RESECTION WITH RESECTION OF CHEST WALL (NOT IDENTIFYING WHICH LOBE RESECTION))</li> <li>• <b>E55.4B</b> (SEGMENTAL RESECTION)</li> <li>• <b>E57.4</b> (OPEN OPERATION ON LUNG (OPEN AND CLOSE) (INCISION OF LUNG NEC))</li> <li>• <b>E57.8</b> (OTHER OPEN OPERATION ON LUNG)</li> <li>• <b>01</b> (EXTRAPLEURAL PNEUMONECTOMY)</li> <li>• <b>02</b> (DEBULKING PLEURECTOMY)</li> <li>• <b>03</b> (PLEURODESIS)</li> </ul>
46.	L22	<i>Did patient have mediastinoscopy/mediastinotomy? (Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
47.	L15	EXCISION MARGIN	<ul style="list-style-type: none"> <li>• <b>X</b> (RX)</li> <li>• <b>0</b> (R0)</li> <li>• <b>1</b> (R1)</li> <li>• <b>2</b> (R2)</li> </ul>
48.	8.16	T CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> </ul>
49.	8.17	N CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> </ul>
50.	8.18	M CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> </ul>

51.	L16	Certainty factor - pathological stage T value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
52.	L17	Certainty factor - pathological stage N value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
53.	L18	Certainty factor - pathological stage M value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
54.	8.19	TNM CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• IA</li> <li>• IB</li> <li>• IIA</li> <li>• IIB</li> <li>• IIIA</li> <li>• IIIB</li> <li>• IV</li> <li>• OCCULT CARCINOMA</li> </ul>
55.	9.1	SITE CODE (OF ANTI- CANCER DRUG TREATMENT)	A valid 5 digit OCS site code
56.	9.4	DECISION TO TREAT DATE (ANTI-CANCER DRUG REGIMEN)	Date: (format CCYY-MM-DD)
57.	9.10	START DATE (ANTI- CANCER DRUG REGIMEN)	Date: (format CCYY-MM-DD)
58.	9.8	DRUG TREATMENT INTENT	<ul style="list-style-type: none"> <li>• <b>A</b> (ADJUVANT)</li> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NEOADJUVANT)</li> <li>• <b>P</b> (PALLIATIVE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
59.	L19	LIKELY TO RECEIVE PROPHYLACTIC CRANIAL IRRADIATION ? (Redundant P2R1)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
60.	10.1	SITE CODE (OF TELETHERAPY)	A valid 5 digit OCS site code
61.	10.3	DECISION TO TREAT DATE (TELETHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
62.	10.6	CANCER TREATMENT INTENT	<ul style="list-style-type: none"> <li>• <b>A</b> (ADJUVANT)</li> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NEOADJUVANT)</li> <li>• <b>P</b> (PALLIATIVE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>

63.	10.7	RADIOTHERAPY ANATOMICAL TREATMENT SITE	<ul style="list-style-type: none"> <li>• <b>Z01.9</b> (TISSUE OF BRAIN (NEC))</li> <li>• <b>Z24.3</b> (TRACHEA)</li> <li>• <b>Z24.6</b> (LUNG AND MEDIASTINUM)</li> <li>• <b>Z24.7</b> (LUNG AND MEDIASTINUM)</li> <li>• <b>Z50.9</b> (SKIN OF OTHER (NEC))</li> <li>• <b>Z52.9</b> (CHEST WALL (NEC))</li> <li>• <b>Z87.1</b> (BONE (NEC))</li> <li>• <b>Z92.9</b> (OTHER REGION OF BODY (NEC))</li> <li>• <b>01</b> (MESOTHELIOMA DRAIN SITE)</li> <li>•</li> </ul>
64.	10.8	START DATE (TELEOTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
65.	11.1	SITE CODE (OF BRACHYTHERAPY)	A valid 5 digit OCS site code
66.	11.3	DECISION TO TREAT DATE (BRACHYTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
67.	11.9	START DATE (BRACHYTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
68.	12.n	SITE CODE (SPECIALIST PALLIATIVE TREATMENT COURSE)	A valid 5 digit OCS site code
69.	12.n	DECISION TO TREAT DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)	Date: (format CCYY-MM-DD)
70.	12.n	START DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)	Date: (format CCYY-MM-DD)
71.	L25	SITE CODE (ACTIVE MONITORING)	A valid 5 digit OCS site code
72.	16.9	DECISION TO TREAT DATE (ACTIVE MONITORING)	Date: (format CCYY-MM-DD)
73.	8.3	INVESTIGATION RESULT DATE	Date: (format CCYY-MM-DD)

74.	8.10	HISTOLOGY (SNOMED)	<ul style="list-style-type: none"> <li>• <b>M8010/2</b> (CARCINOMA IN SITU)</li> <li>• <b>M8010/6</b> (SECONDARY CARCINOMA)</li> <li>• <b>M8012/3</b> (LARGE CELL CARCINOMA NOS)</li> <li>• <b>M8013/3</b> (LARGE CELL NEUROENDOCRINE (ICD-O-3))</li> <li>• <b>M8020/3</b> (LARGE CELL – UNDIFFERENTIATED)</li> <li>• <b>M8041/3</b> (SMALL CELL CARCINOMA)</li> <li>• <b>M8046/3</b> (NON-SMALL CELL CARCINOMA (ICD-O-3))</li> <li>• <b>M8070/3</b> (SQUAMOUS CELL CARCINOMA NOS)</li> <li>• <b>M8140/3</b> (ADENOCARCINOMA NOS)</li> <li>• <b>M8240/3</b> (CARCINOID NOS)</li> <li>• <b>M8250/3</b> (BRONCHIO-ALVEOLAR CELL CARCINOMA)</li> <li>• <b>M8940/3</b> (MIXED TUMOUR)</li> <li>• <b>M8980/3</b> (CARCINOSARCOMA NOS)</li> <li>• <b>M9050/3</b> (MALIGNANT MESOTHELIOMA (NOS))</li> <li>• <b>M9052/3</b> (MESOTHELIOMA (EPITHELIOID))</li> <li>• <b>M9051/3</b> (MESOTHELIOMA (SARCOMATOID) ICD-O-3)</li> <li>• <b>M9053/3</b> (BIPHASIC MESOTHELIOMA)</li> <li>• <b>M9999/9</b> (OTHER)</li> </ul>
75.	L23	POST TREATMENT: SITE SPECIFIC CLASSIFICATION	<ul style="list-style-type: none"> <li>• <b>1</b> (LIMITED DISEASE)</li> <li>• <b>2</b> (EXTENSIVE DISEASE)</li> <li>• <b>X</b> (UNKNOWN)</li> </ul>
76.	13.1	PATIENT TRIAL STATUS (CANCER)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
77.	15.1	DEATH DATE	Date: (format CCYY-MM-DD)
78.	L20	DEATH – WAS DEATH RELATED TO TREATMENT	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
79.	14.7	TREATMENT MORBIDITY TYPE (CANCER)	<ul style="list-style-type: none"> <li>• <b>1</b> (SURGERY)</li> <li>• <b>2</b> (CHEMOTHERAPY)</li> <li>• <b>3</b> (RADIOTHERAPY)</li> <li>• <b>4</b> (COMBINATION)</li> </ul>

80.	L21	CONFIRM IF PATIENT RECEIVED PROPHYLACTIC CRANIAL IRRADIATION	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
81.	L26	RADIOTHERAPY TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• <b>01</b> (CURATIVE - RADICAL RT)</li> <li>• <b>02</b> (CURATIVE - CHART/CHARTWEL)</li> <li>• <b>03</b> (PART OF CHEMO/RT TREATMENT PLAN)</li> <li>• <b>04</b> (ADJUVANT FOLLOWING SURGICAL TREATMENT)</li> <li>• <b>05</b> (PALLIATIVE RADIOTHERAPY)</li> </ul>
82.	L27	CHEMOTHERAPY TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• <b>01</b> (CHEMOTHERAPY ALONE)</li> <li>• <b>02</b> (NEO-ADJUVANT CHEMOTHERAPY BEFORE SURGERY)</li> <li>• <b>03</b> (PART OF CHEMO/RT TREATMENT PLAN)</li> <li>• <b>04</b> (ADJUVANT CHEMOTHERAPY POST SURGERY)</li> <li>• <b>05</b> (INDUCTION CHEMOTHERAPY TO DOWN STAGE BEFORE SURGERY)</li> </ul>
83.	L28	TREATMENT PLAN TYPE	<ul style="list-style-type: none"> <li>• <b>01</b> (SINGLE MODALITY)</li> <li>• <b>02</b> (MULTIPLE MODALITY)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
84.	L29	SUGGESTED CANCER TREATMENT PLAN	<ul style="list-style-type: none"> <li>• <b>01</b> (SURGERY)</li> <li>• <b>02</b> (TELETHERAPY (RADIOTHERAPY))</li> <li>• <b>03</b> (CHEMOTHERAPY)</li> <li>• <b>04</b> (BRACHYTHERAPY)</li> <li>• <b>05</b> (PALLIATIVE CARE)</li> <li>• <b>06</b> (ACTIVE MONITORING)</li> <li>• <b>07</b> (SEQUENTIAL CHEMOTHERAPY AND RADIOTHERAPY)</li> <li>• <b>08</b> (CONCURRENT CHEMOTHERAPY AND RADIOTHERAPY)</li> <li>• <b>09</b> (INDUCTION CHEMOTHERAPY TO DOWN STAGE BEFORE SURGERY)</li> <li>• <b>10</b> (NEO-ADJUVANT CHEMOTHERAPY AND SURGERY)</li> <li>• <b>11</b> (SURGERY FOLLOWED BY ADJUVANT CHEMOTHERAPY)</li> </ul>

85.	L30	ORIGINAL TREATMENT PLAN CARRIED OUT	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
86.	L31	ORIGINAL TREATMENT PLAN FAILURE REASON	<ul style="list-style-type: none"> <li>• 01 (CANCER PROGRESSED THROUGH TREATMENT SUCH THAT A NEW TREATMENT PLAN REQUIRED)</li> <li>• 02 (PATIENT CHOICE)</li> <li>• 03 (PATIENT DIED)</li> <li>• 04 (TREATMENT TOXICITY)</li> <li>• 05 (DISEASE PROGRESSION)</li> </ul>
87.	L32	REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT	<ul style="list-style-type: none"> <li>• 01 (REFUSED)</li> <li>• 03 (CO-MORBIDITY PRECLUDING TREATMENT)</li> <li>• 06 (DIED)</li> <li>• L4 (COPD)</li> </ul>
88.	3.3(2A or 2B)	CT SCAN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
89.	3.2	DATE OF CT SCAN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
90.	3.3(4)	PET OR PET/CT SCAN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
91.	3.2	DATE OF PET OR PET/CT SCAN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
92.	L33	BRONCHOSCOPY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
93.	L34	DATE OF BRONCHOSCOPY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
94.	L35	DIAGNOSTIC BIOPSY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
95.	L36	DATE OF DIAGNOSTIC BIOPSY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
96.	L37	CT GUIDED BIOPSY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
97.	L38	DATE OF CT GUIDED BIOPSY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
98.	L39	PALLIATIVE CARE.PROVIDER TYPE	<ul style="list-style-type: none"> <li>• 01 (HOSPITAL)</li> <li>• 02 (COMMUNITY)</li> </ul>
99.	L40	PALLIATIVE CARE.COMMUNITY PROVIDER TYPE	<ul style="list-style-type: none"> <li>• 01 (HOSPICE)</li> <li>• 02 (NURSING HOME)</li> <li>• 03 (HOME CARE)</li> <li>• 08 (OTHER)</li> <li>• 9 (UNKNOWN)</li> </ul>
100.	L41	PALLIATIVE CARE.INTERVENTIONAL TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>

<b>101.</b>	L42	DATE INTERVENTIONAL TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
<b>102.</b>	L43	STAGING PROCEDURE PERFORMED	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
<b>103.</b>	L22	STAGING PROCEDURE MEDIASTINOSCOPY MEDIASTINOTOMY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
<b>104.</b>	L44	STAGING PROCEDURE PERFORMED FNA	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
<b>105.</b>	L45	STAGING PROCEDURE OTHER STAGING	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
<b>106.</b>	L46	STAGING PROCEDURE UNKNOWN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
<b>107.</b>	L47	PATIENT ASSESSED BY A LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>
<b>108.</b>	L48	DATE FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
<b>109.</b>	L49	HOW WAS PATIENT FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• 1 (IN CLINIC)</li> <li>• 2 (HOME VISIT)</li> <li>• 3 (WARD VISIT)</li> <li>• 4 (TELEPHONE)</li> <li>• 8 (OTHER)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>
<b>110.</b>	L50	AT WHAT STAGE(S) IN THE PATIENT PATHWAY DID ASSESSMENT BY LUNG CANCER NURSE SPECIALIST OCCUR	<ul style="list-style-type: none"> <li>• 1 (BEFORE DIAGNOSIS)</li> <li>• 2 (WHEN PATIENT RECEIVED DIAGNOSIS ONLY)</li> <li>• 3 (AFTER DIAGNOSIS)</li> <li>• 4 (BEFORE AND AFTER DIAGNOSIS)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>
<b>111.</b>	L51	LUNG CANCER NURSE SPECIALIST PRESENT WHEN PATIENT RECEIVED DIAGNOSIS	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>

### 2.2.8. Data Items (Download All Organisations – Identifiable)

This is an alternative download of all data held on LUCADA. This replaces the anonymised download for RCP with one containing patient identifiable data for use by Cancer Registries. This and the anonymised download are mutually exclusive.

Field No.	NCDS v4.5	NCDS Item Name (v3.0)	Permitted values (in bold)
0.		LUCADA Unique Identifier	Numeric
1.		DATE/TIME OF DOWNLOAD	DD/MM/YYYY HH.MM
2.	1.1	NHS NUMBER	Format (10N). 10 digit numeric
3.	1.9	SEX	<ul style="list-style-type: none"> <li>• <b>1</b> (MALE)</li> <li>• <b>2</b> (FEMALE)</li> <li>• <b>0</b> (UNKNOWN)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
4.	DERIVED	Age at time of diagnosis	Age (numeric, whole years). This is a derived field.
5.	1.8	POSTCODE OF USUAL ADDRESS (AT DIAGNOSIS)	The patient's postcode
6.	1.3	ORGANISATION CODE (CODE OF PROVIDER)	
7.	1.4	CARE SPELL IDENTIFIER	Numeric
8.	2.1	SOURCE OF REFERRAL (FOR CANCER)	<ul style="list-style-type: none"> <li>• <b>01</b> (FOLLOWING AN EMERGENCY ADMISSION)</li> <li>• <b>02</b> (FOLLOWING A DOMICILIARY VISIT)</li> <li>• <b>03</b> (REFERRAL FROM GP)</li> <li>• <b>05</b> (REFERRAL FROM A CONSULTANT OTHER THAN IN AN A&amp;E DEPARTMENT)</li> <li>• <b>06</b> (SELF-REFERRAL)</li> <li>• <b>08</b> (OTHER SOURCE OF REFERRAL)</li> <li>• <b>10</b> (FOLLOWING A&amp;E ATTENDANCE)</li> <li>• <b>92</b> (GENERAL DENTAL PRACTITIONER)</li> <li>• <b>93</b> (COMMUNITY DENTAL SERVICE)</li> <li>• <b>99</b> (NOT KNOWN)</li> </ul>
9.	2.5	CANCER REFERRAL DECISION DATE	Date: (format CCYY-MM-DD)
10.	2.9	DATE FIRST SEEN	Date: (format CCYY-MM-DD)
11.	1.3	SITE CODE OF PLACE FIRST SEEN	A valid 5 digit OCS site code
12.	L24	LUNG CANCER SPECIALIST REFERRAL DATE	Date: (format CCYY-MM-DD)
13.	4.1	DIAGNOSIS DATE (CANCER)	Date: (format CCYY-MM-DD)

14.	1.3	SITE CODE (DIAGNOSIS)	A valid 5 digit OCS site code
-----	-----	-----------------------	-------------------------------

<p>15.</p>	<p>4.2</p>	<p>PRIMARY DIAGNOSIS (ICD)</p>	<ul style="list-style-type: none"> <li>• <b>C33</b> (TRACHEA)</li> <li>• <b>C34</b> (MALIGNANT NEOPLASM OF BRONCHUS OR LUNG)</li> <li>• <b>C34.0</b> (MAIN BRONCHUS, CARINA, HILUS OF LUNG)</li> <li>• <b>C34.1</b> (UPPER LOBE, BRONCHUS OR LUNG (INCLUDING PANCOAST))</li> <li>• <b>C34.2</b> (MIDDLE LOBE / LINGULAR, BRONCHUS OR LUNG)</li> <li>• <b>C34.3</b> (LOWER LOBE, BRONCHUS OR LUNG)</li> <li>• <b>C34.8</b> (OVERLAPPING LESION OF BRONCHUS AND LUNG)</li> <li>• <b>C34.9</b> (BRONCHUS OR LUNG, UNSPECIFIED)</li> <li>• <b>C38</b> (MALIGNANT NEOPLASM OF HEART, MEDIASTINUM AND PLEURA)</li> <li>• <b>C38.3</b> (MEDIASTINUM, PART UNSPECIFIED)</li> <li>• <b>C38.4</b> (PLEURA)</li> <li>• <b>C38.8</b> (OVERLAPPING LESION OF HEART, MEDIASTINUM AND PLEURA)</li> <li>• <b>C45</b> (MESOTHELIOMA)</li> <li>• <b>C45.0</b> (MESOTHELIOMA OF PLEURA)</li> </ul>
------------	------------	--------------------------------	---

16.	4.3	TUMOUR LATERALITY	<ul style="list-style-type: none"> <li>• <b>B</b> (BILATERAL)</li> <li>• <b>L</b> (LEFT)</li> <li>• <b>M</b> (MIDLINE)</li> <li>• <b>R</b> (RIGHT)</li> <li>• <b>8</b> (NOT APPLICABLE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
17.	4.4	BASIS OF DIAGNOSIS (CANCER)	<ul style="list-style-type: none"> <li>• <b>0</b> (DEATH CERTIFICATE)</li> <li>• <b>1</b> (CLINICAL)</li> <li>• <b>2</b> (CLINICAL INVESTIGATION)</li> <li>• <b>4</b> (SPECIFIC TUMOUR MARKERS)</li> <li>• <b>5</b> (CYTOLOGY)</li> <li>• <b>6</b> (HISTOLOGY OF A METASTASIS)</li> <li>• <b>7</b> (HISTOLOGY OF A PRIMARY TUMOUR)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
18.	6.1	T CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> </ul>
19.	6.3	N CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> </ul>
20.	6.5	M CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> </ul>
21.	6.2	STAGING CERTAINTY FACTOR (T CATEGORY) <i>(Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
22.	6.4	STAGING CERTAINTY FACTOR (N CATEGORY) <i>(Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
23.	6.6	STAGING CERTAINTY FACTOR (M CATEGORY) <i>(Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>

24.	6.7	TNM CATEGORY (FINAL PRE-TREATMENT)	<ul style="list-style-type: none"> <li>• IA</li> <li>• IB</li> <li>• IIA</li> <li>• IIB</li> <li>• IIIA</li> <li>• IIIB</li> <li>• IV</li> <li>• OCCULT CARCINOMA</li> </ul>
25.	4.5	HISTOLOGY (SNOMED)	<ul style="list-style-type: none"> <li>• <b>M8010/2</b> (CARCINOMA IN SITU)</li> <li>• <b>M8010/6</b> (SECONDARY CARCINOMA)</li> <li>• <b>M8012/3</b> (LARGE CELL CARCINOMA NOS)</li> <li>• <b>M8013/3</b> (LARGE CELL NEUROENDOCRINE (ICD-O-3))</li> <li>• <b>M8020/3</b> (LARGE CELL – UNDIFFERENTIATED)</li> <li>• <b>M8041/3</b> (SMALL CELL CARCINOMA)</li> <li>• <b>M8046/3</b> (NON-SMALL CELL CARCINOMA (ICD-O-3))</li> <li>• <b>M8070/3</b> (SQUAMOUS CELL CARCINOMA NOS)</li> <li>• <b>M8140/3</b> (ADENOCARCINOMA NOS)</li> <li>• <b>M8240/3</b> (CARCINOID NOS)</li> <li>• <b>M8250/3</b> (BRONCHIO-ALVEOLAR CELL CARCINOMA)</li> <li>• <b>M8940/3</b> (MIXED TUMOUR)</li> <li>• <b>M8980/3</b> (CARCINOSARCOMA NOS)</li> <li>• <b>M9050/3</b> (MALIGNANT MESOTHELIOMA (NOS))</li> <li>• <b>M9051/3</b> (MESOTHELIOMA (SARCOMATOID) ICD-O-3)</li> <li>• <b>M9052/3</b> (MESOTHELIOMA (EPITHELIOID))</li> <li>• <b>M9053/3</b> (BIPHASIC MESOTHELIOMA)</li> <li>• <b>M9999/9</b> (OTHER)</li> </ul>
26.	6.9	SITE-SPECIFIC STAGING CLASSIFICATION	<ul style="list-style-type: none"> <li>• <b>1</b> (LIMITED DISEASE)</li> <li>• <b>2</b> (EXTENSIVE DISEASE)</li> <li>• <b>X</b> (UNKNOWN)</li> </ul>
27.	5.1	MDT DISCUSSION INDICATOR	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
28.	5.2	MULTIDISCIPLINARY TEAM DISCUSSION DATE	Date: (format CCYY-MM-DD)

29.	5.3	CARE PLAN AGREED DATE (Redundant P2R1)	Date: (format CCYY-MM-DD)
30.	5.5	CANCER CARE PLAN INTENT	<ul style="list-style-type: none"> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NO SPECIFIC ANTI-CANCER TREATMENT)</li> <li>• <b>P</b> (PALLIATIVE ANTI-CANCER)</li> <li>• <b>S</b> (SUPPORTING TREATMENT)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
31.	L7	Is there significant co-morbidity? (Redundant P2R1)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
32.	L8	Date co-morbidity recorded (Redundant P2R1)	Date: (format CCYY-MM-DD)
33.	L4	COPD (Redundant P2R1)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
34.	L10	Dementia/cerebrovascular disease	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
35.	L9	Cardiovascular disease	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
36.	L11	Renal failure	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
37.	L12	Other malignancy	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
38.	L13	Severe weight loss	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
39.	L14	Other significant co-morbidity	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
40.	L5	FEV1 ABSOLUTE AMOUNT	Format (99.99) Up to 2 decimal places (0.1 to 10.00 inclusive)
41.	L6	FEV1 PERCENTAGE	Format (999) (1 to 150 inclusive)
42.	5.10	PERFORMANCE STATUS (ADULT)	<ul style="list-style-type: none"> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
43.	7.1	SITE CODE (OF SURGERY)	A valid 5 digit OCS site code
44.	7.5	DECISION TO TREAT DATE (SURGERY)	Date: (format CCYY-MM-DD)
45.	7.9	PROCEDURE DATE (SURGERY)	Date: (format CCYY-MM-DD)

46.	7.10	PRIMARY PROCEDURE (OPCS)	<ul style="list-style-type: none"> <li>• <b>E44.1</b> (CARINAL RESECTION)</li> <li>• <b>E54.1</b> (PNEUMONECTOMY)</li> <li>• <b>E54.2</b> (BILOBECTOMY)</li> <li>• <b>E54.3</b> (LOBECTOMY)</li> <li>• <b>E54.4A</b> (WEDGE RESECTION OF LESION OF LUNG (SEGMENT))</li> <li>• <b>E54.8A</b> (MULTIPLE WEDGES RESECTED)</li> <li>• <b>E54.8B</b> (SLEEVE RESECTION)</li> <li>• <b>E54.8 +T01</b> (LUNG RESECTION WITH RESECTION OF CHEST WALL (NOT IDENTIFYING WHICH LOBE RESECTION))</li> <li>• <b>E55.4B</b> (SEGMENTAL RESECTION)</li> <li>• <b>E57.4</b> (OPEN OPERATION ON LUNG (OPEN AND CLOSE) (INCISION OF LUNG NEC))</li> <li>• <b>E57.8</b> (OTHER OPEN OPERATION ON LUNG)</li> <li>• <b>01</b> (EXTRAPLEURAL PNEUMONECTOMY)</li> <li>• <b>02</b> (DEBULKING PLEURECTOMY)</li> <li>• <b>03</b> (PLEURODESIS)</li> </ul>
47.	L22	<i>Did patient have mediastinoscopy/mediastinotomy? (Redundant P2R1)</i>	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
48.	L15	EXCISION MARGIN	<ul style="list-style-type: none"> <li>• <b>X</b> (RX)</li> <li>• <b>0</b> (R0)</li> <li>• <b>1</b> (R1)</li> <li>• <b>2</b> (R2)</li> </ul>
49.	8.16	T CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> </ul>
50.	8.17	N CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> <li>• 2</li> <li>• 3</li> </ul>
51.	8.18	M CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• X</li> <li>• 0</li> <li>• 1</li> </ul>

52.	L16	Certainty factor - pathological stage T value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
53.	L17	Certainty factor - pathological stage N value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
54.	L18	Certainty factor - pathological stage M value (Redundant P2R1)	<ul style="list-style-type: none"> <li>• 1</li> <li>• 2</li> <li>• 3</li> <li>• 4</li> <li>• 5</li> </ul>
55.	8.19	TNM CATEGORY (PATHOLOGICAL)	<ul style="list-style-type: none"> <li>• IA</li> <li>• IB</li> <li>• IIA</li> <li>• IIB</li> <li>• IIIA</li> <li>• IIIB</li> <li>• IV</li> <li>• OCCULT CARCINOMA</li> </ul>
56.	9.1	SITE CODE (OF ANTI- CANCER DRUG TREATMENT)	A valid 5 digit OCS site code
57.	9.4	DECISION TO TREAT DATE (ANTI-CANCER DRUG REGIMEN)	Date: (format CCYY-MM-DD)
58.	9.10	START DATE (ANTI- CANCER DRUG REGIMEN)	Date: (format CCYY-MM-DD)
59.	9.8	DRUG TREATMENT INTENT	<ul style="list-style-type: none"> <li>• <b>A</b> (ADJUVANT)</li> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NEOADJUVANT)</li> <li>• <b>P</b> (PALLIATIVE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
60.	L19	LIKELY TO RECEIVE PROPHYLACTIC CRANIAL IRRADIATION ? (Redundant P2R1)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
61.	10.1	SITE CODE (OF TELETHERAPY)	A valid 5 digit OCS site code
62.	10.3	DECISION TO TREAT DATE (TELETHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
63.	10.6	CANCER TREATMENT INTENT	<ul style="list-style-type: none"> <li>• <b>A</b> (ADJUVANT)</li> <li>• <b>C</b> (CURATIVE)</li> <li>• <b>N</b> (NEOADJUVANT)</li> <li>• <b>P</b> (PALLIATIVE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>

64.	10.7	RADIOTHERAPY ANATOMICAL TREATMENT SITE	<ul style="list-style-type: none"> <li>• <b>Z01.9</b> (TISSUE OF BRAIN (NEC))</li> <li>• <b>Z24.3</b> (TRACHEA)</li> <li>• <b>Z24.6</b> (LUNG AND MEDIASTINUM)</li> <li>• <b>Z24.7</b> (LUNG AND MEDIASTINUM)</li> <li>• <b>Z50.9</b> (SKIN OF OTHER (NEC))</li> <li>• <b>Z52.9</b> (CHEST WALL (NEC))</li> <li>• <b>Z87.1</b> (BONE (NEC))</li> <li>• <b>Z92.9</b> (OTHER REGION OF BODY (NEC))</li> <li>• <b>01</b> (MESOTHELIOMA DRAIN SITE)</li> <li>•</li> </ul>
65.	10.8	START DATE (TELEOTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
66.	11.1	SITE CODE (OF BRACHYTHERAPY)	A valid 5 digit OCS site code
67.	11.3	DECISION TO TREAT DATE (BRACHYTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
68.	11.9	START DATE (BRACHYTHERAPY TREATMENT COURSE)	Date: (format CCYY-MM-DD)
69.	12.n	SITE CODE (SPECIALIST PALLIATIVE TREATMENT COURSE)	A valid 5 digit OCS site code
70.	12.n	DECISION TO TREAT DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)	Date: (format CCYY-MM-DD)
71.	12.n	START DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)	Date: (format CCYY-MM-DD)
72.	L25	SITE CODE (ACTIVE MONITORING)	A valid 5 digit OCS site code
73.	16.9	DECISION TO TREAT DATE (ACTIVE MONITORING)	Date: (format CCYY-MM-DD)
74.	8.3	INVESTIGATION RESULT DATE	Date: (format CCYY-MM-DD)


75.	8.10	HISTOLOGY (SNOMED)	<ul style="list-style-type: none"> <li>• <b>M8010/2</b> (CARCINOMA IN SITU)</li> <li>• <b>M8010/6</b> (SECONDARY CARCINOMA)</li> <li>• <b>M8012/3</b> (LARGE CELL CARCINOMA NOS)</li> <li>• <b>M8013/3</b> (LARGE CELL NEUROENDOCRINE (ICD-O-3))</li> <li>• <b>M8020/3</b> (LARGE CELL – UNDIFFERENTIATED)</li> <li>• <b>M8041/3</b> (SMALL CELL CARCINOMA)</li> <li>• <b>M8046/3</b> (NON-SMALL CELL CARCINOMA (ICD-O-3))</li> <li>• <b>M8070/3</b> (SQUAMOUS CELL CARCINOMA NOS)</li> <li>• <b>M8140/3</b> (ADENOCARCINOMA NOS)</li> <li>• <b>M8240/3</b> (CARCINOID NOS)</li> <li>• <b>M8250/3</b> (BRONCHIO-ALVEOLAR CELL CARCINOMA)</li> <li>• <b>M8940/3</b> (MIXED TUMOUR)</li> <li>• <b>M8980/3</b> (CARCINOSARCOMA NOS)</li> <li>• <b>M9050/3</b> (MALIGNANT MESOTHELIOMA (NOS))</li> <li>• <b>M9052/3</b> (MESOTHELIOMA (EPITHELIOD))</li> <li>• <b>M9051/3</b> (MESOTHELIOMA (SARCOMATOID) ICD-O-3)</li> <li>• <b>M9053/3</b> (BIPHASIC MESOTHELIOMA)</li> <li>• <b>M9999/9</b> (OTHER)</li> </ul>
76.	L23	POST TREATMENT: SITE SPECIFIC CLASSIFICATION	<ul style="list-style-type: none"> <li>• <b>1</b> (LIMITED DISEASE)</li> <li>• <b>2</b> (EXTENSIVE DISEASE)</li> <li>• <b>X</b> (UNKNOWN)</li> </ul>
77.	13.1	PATIENT TRIAL STATUS (CANCER)	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> </ul>
78.	15.1	DEATH DATE	Date: (format CCYY-MM-DD)
79.	L20	DEATH – WAS DEATH RELATED TO TREATMENT	<ul style="list-style-type: none"> <li>• <b>Y</b> (TRUE)</li> <li>• <b>N</b> (FALSE)</li> <li>• <b>9</b> (UNKNOWN)</li> </ul>
80.	14.7	TREATMENT MORBIDITY TYPE (CANCER)	<ul style="list-style-type: none"> <li>• <b>1</b> (SURGERY)</li> <li>• <b>2</b> (CHEMOTHERAPY)</li> <li>• <b>3</b> (RADIOTHERAPY)</li> <li>• <b>4</b> (COMBINATION)</li> </ul>

81.	L21	CONFIRM IF PATIENT RECEIVED PROPHYLACTIC CRANIAL IRRADIATION	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
82.	L26	RADIOTHERAPY TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• 01 (CURATIVE - RADICAL RT)</li> <li>• 02 (CURATIVE - CHART/CHARTWEL)</li> <li>• 03 (PART OF CHEMO/RT TREATMENT PLAN)</li> <li>• 04 (ADJUVANT FOLLOWING SURGICAL TREATMENT)</li> <li>• 05 (PALLIATIVE RADIOTHERAPY)</li> </ul>
83.	L27	CHEMOTHERAPY TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• 01 (CHEMOTHERAPY ALONE)</li> <li>• 02 (NEO-ADJUVANT CHEMOTHERAPY BEFORE SURGERY)</li> <li>• 03 (PART OF CHEMO/RT TREATMENT PLAN)</li> <li>• 04 (ADJUVANT CHEMOTHERAPY POST SURGERY)</li> <li>• 05 (INDUCTION CHEMOTHERAPY TO DOWN STAGE BEFORE SURGERY)</li> </ul>
84.	L28	TREATMENT PLAN TYPE	<ul style="list-style-type: none"> <li>• 01 (SINGLE MODALITY)</li> <li>• 02 (MULTIPLE MODALITY)</li> <li>• 9 (UNKNOWN)</li> </ul>
85.	L29	SUGGESTED CANCER TREATMENT PLAN	<ul style="list-style-type: none"> <li>• 01 (SURGERY)</li> <li>• 02 (TELETHERAPY (RADIOTHERAPY))</li> <li>• 03 (CHEMOTHERAPY)</li> <li>• 04 (BRACHYTHERAPY)</li> <li>• 05 (PALLIATIVE CARE)</li> <li>• 06 (ACTIVE MONITORING)</li> <li>• 07 (SEQUENTIAL CHEMOTHERAPY AND RADIOTHERAPY)</li> <li>• 08 (CONCURRENT CHEMOTHERAPY AND RADIOTHERAPY)</li> <li>• 09 (INDUCTION CHEMOTHERAPY TO DOWN STAGE BEFORE SURGERY)</li> <li>• 10 (NEO-ADJUVANT CHEMOTHERAPY AND SURGERY)</li> <li>• 11 (SURGERY FOLLOWED BY ADJUVANT CHEMOTHERAPY)</li> </ul>

86.	L30	ORIGINAL TREATMENT PLAN CARRIED OUT	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
87.	L31	ORIGINAL TREATMENT PLAN FAILURE REASON	<ul style="list-style-type: none"> <li>• 01 (CANCER PROGRESSED THROUGH TREATMENT SUCH THAT A NEW TREATMENT PLAN REQUIRED)</li> <li>• 02 (PATIENT CHOICE)</li> <li>• 03 (PATIENT DIED)</li> <li>• 04 (TREATMENT TOXICITY)</li> <li>• 05 (DISEASE PROGRESSION)</li> </ul>
88.	L32	REASON PATIENT DID NOT RECEIVE FIRST CHOICE TREATMENT	<ul style="list-style-type: none"> <li>• 01 (REFUSED)</li> <li>• 03 (CO-MORBIDITY PRECLUDING TREATMENT)</li> <li>• 06 (DIED)</li> <li>• L4 (COPD)</li> </ul>
89.	3.3(2A or 2B)	CT SCAN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
90.	3.2	DATE OF CT SCAN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
91.	3.3(4)	PET OR PET/CT SCAN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
92.	3.2	DATE OF PET OR PET/CT SCAN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
93.	L33	BRONCHOSCOPY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
94.	L34	DATE OF BRONCHOSCOPY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
95.	L35	DIAGNOSTIC BIOPSY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
96.	L36	DATE OF DIAGNOSTIC BIOPSY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
97.	L37	CT GUIDED BIOPSY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
98.	L38	DATE OF CT GUIDED BIOPSY	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
99.	L39	PALLIATIVE CARE.PROVIDER TYPE	<ul style="list-style-type: none"> <li>• 01 (HOSPITAL)</li> <li>• 02 (COMMUNITY)</li> </ul>
100.	L40	PALLIATIVE CARE.COMMUNITY PROVIDER TYPE	<ul style="list-style-type: none"> <li>• 01 (HOSPICE)</li> <li>• 02 (NURSING HOME)</li> <li>• 03 (HOME CARE)</li> <li>• 08 (OTHER)</li> <li>• 9 (UNKNOWN)</li> </ul>
101.	L41	PALLIATIVE CARE.INTERVENTIONAL TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>

<b>102.</b>	L42	DATE INTERVENTIONAL TREATMENT GIVEN	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
<b>103.</b>	L43	STAGING PROCEDURE PERFORMED	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> </ul>
<b>104.</b>	L22	STAGING PROCEDURE MEDIASTINOSCOPY MEDIASTINOTOMY	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
<b>105.</b>	L44	STAGING PROCEDURE PERFORMED FNA	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
<b>106.</b>	L45	STAGING PROCEDURE OTHER STAGING	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
<b>107.</b>	L46	STAGING PROCEDURE UNKNOWN	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> </ul>
<b>108.</b>	L47	PATIENT ASSESSED BY A LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>
<b>109.</b>	L48	DATE FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• Date: (format CCYY-MM-DD)</li> </ul>
<b>110.</b>	L49	HOW WAS PATIENT FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST	<ul style="list-style-type: none"> <li>• 1 (IN CLINIC)</li> <li>• 2 (HOME VISIT)</li> <li>• 3 (WARD VISIT)</li> <li>• 4 (TELEPHONE)</li> <li>• 8 (OTHER)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>
<b>111.</b>	L50	AT WHAT STAGE(S) IN THE PATIENT PATHWAY DID ASSESSMENT BY LUNG CANCER NURSE SPECIALIST OCCUR	<ul style="list-style-type: none"> <li>• 1 (BEFORE DIAGNOSIS)</li> <li>• 2 (WHEN PATIENT RECEIVED DIAGNOSIS ONLY)</li> <li>• 3 (AFTER DIAGNOSIS)</li> <li>• 4 (BEFORE AND AFTER DIAGNOSIS)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>
<b>112.</b>	L51	LUNG CANCER NURSE SPECIALIST PRESENT WHEN PATIENT RECEIVED DIAGNOSIS	<ul style="list-style-type: none"> <li>• Y (TRUE)</li> <li>• N (FALSE)</li> <li>• 9 (UNKNOWN)</li> <li>• 99 (NOT RECORDED)</li> </ul>





## 6. Appendix C – Cell headings

"NHS NUMBER","PATIENT FORENAME","PATIENT SURNAME","DATE OF BIRTH","SEX","AGE AT DATE OF DIAGNOSIS","POSTCODE OF USUAL ADDRESS","CODE OF PROVIDER","CARE SPELL IDENTIFIER","SOURCE OF REFERRAL (FOR CANCER)","CANCER REFERRAL DECISION DATE","DATE FIRST SEEN","SITE CODE(PLACE FIRST SEEN)","LUNG CANCER SPECIALIST REFERRAL DATE","DIAGNOSIS DATE (CANCER)","SITE CODE (DIAGNOSIS)","PRIMARY DIAGNOSIS (ICD)","TUMOUR LATERALITY","BASIS OF DIAGNOSIS (CANCER)","T CATEGORY (FINAL PRE-TREATMENT)","N CATEGORY (FINAL PRE-TREATMENT)","M CATEGORY (FINAL PRE-TREATMENT)","STAGING CERTAINTY FACTOR (T CATEGORY)","STAGING CERTAINTY FACTOR (N CATEGORY)","STAGING CERTAINTY FACTOR (M CATEGORY)","TNM CATEGORY (FINAL PRE-TREATMENT)","HISTOLOGY (SNOMED)","SITE-

SPECIFIC STAGING CLASSIFICATION", "MDT DISCUSSION INDICATOR", "MULTIDISCIPLINARY TEAM DISCUSSION DATE", " CARE PLAN AGREED DATE", "CANCER CARE PLAN INTENT", "IS THERE SIGNIFICANT CO-MORBIDITY?", " DATE CO-MORBIDITY RECORDED", " COPD", "DEMENTIA/CEREBROVASCULAR DISEASE", "CARDIOVASCULAR DISEASE", "RENAL FAILURE", "OTHER MALIGNANCY", "SEVERE WEIGHT LOSS", "OTHER SIGNIFICANT CO-MORBIDITY", "FEV1 ABSOLUTE AMOUNT", "FEV1 PERCENTAGE", "PERFORMANCE STATUS (ADULT)", "SITE CODE (OF SURGERY)", "DECISION TO TREAT DATE (SURGERY)", "PROCEDURE DATE (SURGERY)", "PRIMARY PROCEDURE (OPCS)", " DID PATIENT HAVE MEDIASTINOSCOPY/MEDIASTINOTOMY?", "EXCISION MARGIN", "T CATEGORY (PATHOLOGICAL)", "N CATEGORY (PATHOLOGICAL)", "M CATEGORY (PATHOLOGICAL)", " CERTAINTY FACTOR - PATHOLOGICAL STAGE T VALUE", " CERTAINTY FACTOR - PATHOLOGICAL STAGE N VALUE", " CERTAINTY FACTOR - PATHOLOGICAL STAGE M VALUE", "TNM CATEGORY (PATHOLOGICAL)", "SITE CODE (OF ANTI-CANCER DRUG TREATMENT)", "DECISION TO TREAT DATE (ANTI-CANCER DRUG REGIMEN)", "START DATE (ANTI-CANCER DRUG REGIMEN)", "DRUG TREATMENT INTENT", " PROPHYLACTIC CRANIAL IRRADIATION", "SITE CODE (OF TELETHERAPY)", "DECISION TO TREAT DATE (TELETHERAPY TREATMENT COURSE)", "CANCER TREATMENT INTENT", "RADIOTHERAPY ANATOMICAL TREATMENT SITE", "START DATE (TELETHERAPY TREATMENT COURSE)", "SITE CODE (OF BRACHYTHERAPY)", "DECISION TO TREAT DATE (BRACHYTHERAPY TREATMENT COURSE)", "START DATE (BRACHYTHERAPY TREATMENT COURSE)", "SITE CODE (SPECIALIST PALLIATIVE TREATMENT COURSE)", "DECISION TO TREAT DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)", "START DATE (SPECIALIST PALLIATIVE TREATMENT COURSE)", "SITE CODE (ACTIVE MONITORING)", "DECISION TO TREAT DATE (ACTIVE MONITORING)", "INVESTIGATION RESULT DATE", "HISTOLOGY (SNOMED)", "POST TREATMENT: SITE SPECIFIC CLASSIFICATION", "PATIENT TRIAL STATUS (CANCER)", "DEATH DATE", "DEATH – WAS DEATH RELATED TO TREATMENT", "TREATMENT MORBIDITY TYPE (CANCER)", "PROPHYLACTIC CRANIAL IRRADIATION", "RADIOTHERAPY TREATMENT GIVEN", "CHEMOTHERAPY TREATMENT GIVEN", "SUGGESTED TREATMENT PLAN", "ORIGINAL PLAN CARRIED OUT", "ORIGINAL PLAN FAILURE REASON", "REASON PATIENT DID NOT RECEIVE FIRST CHOICE", "CT SCAN", "DATE OF CT SCAN", "PET/PET CT SCAN", "DATE OF PET/PET CT SCAN", "BRONCHOSCOPY", "DATE OF BRONCHOSCOPY", "DIAGNOSTIC BIOPSY", "DATE OF DIAGNOSTIC BIOPSY", "CT GUIDED BIOPSY", "DATE OF CT GUIDED BIOPSY", "PALLIATIVE CARE PROVIDER TYPE", "PALLIATIVE CARE INTERVENTIONAL CARE GIVEN", "DATE INTERVENTIONAL CARE GIVEN", "STAGING PROCEDURE PERFORMED", "MEDIASTINOSCOPY OR MEDIASTINOTOMY", "FNA", "OTHER", "UNKNOWN STAGING PROCEDURE", "ASSESSED BY A LUNG CANCER NURSE SPECIALIST", "DATE FIRST ASSESSED BY LUNG CANCER NURSE SPECIALIST", "HOW WAS PATIENT FIRST ASSESSED BY LUNG CANCER

NURSE SPECIALIST", "AT WHAT STAGE(S) IN THE PATIENT PATHWAY  
DID ASSESSMENT BY LUNG CANCER NURSE SPECIALIST  
OCCUR", "LUNG CANCER NURSE SPECIALIST PRESENT WHEN PATIENT  
RECEIVED DIAGNOSIS"